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“ Quanto manca alla vetta?” 
“Tu sali, e non pensarci!” 
F. W. Nietzsche 
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Abstract 
The aim of this thesis was to characterize the in vitro osteogenic differentiation of 
dental pulp stem cells (DPSCs) in 2D cultures and 3D biomaterials. DPSCs, separated 
from dental pulp by enzymatic digestion and isolated by magnetic cell sorting, were 
differentiated toward osteogenic lineage on 2D surface by using an osteogenic medium. 
During the differentiation process, DPSCs expressed specific bone proteins like Runx-2, 
Osx, OPN and OCN sequentially, as occurring during osteoblast differentiation, and 
produced extracellular calcium deposits in vitro. DPSCs were then cultured on 3D 
distinct bioscaffolds, Matrigel
TM
, Collagen sponge, P(d,l)LA and Silk fibroin, and 
analyzed for their ability to differentiate into osteoblastic cells in vivo.  With the 
addition of a third dimension, osteogenic differentiation and mineralized extracellular 
matrix production significantly improved. In particular, in Matrigel
TM
 DPSCs 
differentiated with osteoblast/osteocyte characteristics and formed calcified nodules 
with a 3D intercellular network. Furthermore, DPSCs differentiated in collagen sponge 
actively secreted human type I collagen micro-fibrils and formed calcified matrix 
containing trabecular-like structures. The effect of pre-differentiation of the stem cells 
in bioscaffolds on the subsequent bone formation in vivo was determined in a rat 
subcutaneous model. This thesis demonstrated the strong potential of DPSCs to produce 
3D mineralized bioengineered constructs in vitro and in vivo and suggested that fibroin 
may be an effective tool for functional repair of critical size bone defects.  
 
Among the many cell types that may be useful in regenerative medicine, mounting 
evidence suggests that human term placenta-derived cells will join the list of significant 
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contributors. The chorionic villi of human term placenta are a rich source of stem cells, 
and the stem cell ―niche‖ within the chorionic tissue regulates how stem cells participate 
in placental tissue generation, maintenance and repair even if the anatomic location of 
the niche has not been defined.  
After enzymatic digestion, stem cells were isolated from human term placenta, using 
MACS® selection: c-Kit
+
 population grew on plastic culture ware and had a fibroblast-
like morphology. PCR and WB analysis showed the expression of Oct4, a pluripotent 
marker, in cultured cells. Using immunohistochemical protocols, we studied the 
expression of c-Kit, Oct4 and Stella in chorion-side of placenta. Cytoplasmatic and 
nuclear staining revealed different morphological localization of stem cells: 1) the 
cytoplasm of perivascular cells were c-Kit
+
; 2) big cells with round morphology had a 
nuclear positivity for Oct4 and a cytoplasmatic positivity for c-Kit: 3) cells localized 
close to syncitiotrophoblast layer had a nuclear positivity for Oct4 and Stella. Taken 
together, our results indicated that chorion-derived placental cells are a convenient 
source of stem cells for cell-based therapy, as well as an ideal target for in utero foetal 
gene therapy. 
Riassunto 
Le DPSCs, estratte dalla polpa dentale a seguito di digestione enzimatica e isolate 
mediante Magnetic cell sorting (MACS®), sono state indotte a differenziare in senso 
osteogenico. Il medium differenziativo e‘ stato aggiunto alle cellule in cultura su vetrini 
Termanox, e le cellule sono state fissate a tempi di coltura diversi, per valutarne il grado 
differenziativo. Durante il processo di differenziamento in senso osteogenico, le DPSCs 
esprimono specifici fattori di trascrizione, quali Runx2 e Osx, e bone proteins, quali 
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OCN e OPN, in una sequenza temporale, analogamente a cio‘ che avviene durante il 
processo di osteogenesi da parte degli osteoblasti. Una ulteriore conferma dello stato 
differenziativo è data dalla produzione di depositi extracellulari di calcio da parte delle 
dDPSCs (DPSCs differenziate) . Per meglio mimare il contesto fisiologico, le dDPSC 
sono state coltivate su distinti supporti 3D: Matrigel™,spugna di collagene, P(d,l)LA e 
Fibroina. Con l‘aggiunta della terza dimensione, il differenziamento osteogenico e la 
produzione di matrice extracellulare mineralizzata hanno ottenuto una notevole 
accelerazione rispetto alle cellule differenziate in 2D. In particolare, nel Matrigel™, le 
dDPSC con caratteristiche di osteoblasti/osteociti mostrano gap-junctions e formano 
noduli calcificati con un network intercellulare piuttosto sviluppato; se coltivate nella 
spugna di collagene secernono attivamente collagene di tipo I, formando micro fibrille e 
strutture similari alle trabecole ossee, circondate da matrice calcificata. 
Successivamente, i complessi cellule-biomateriali sono stati testati in vivo (impianti 
ectopici): studi preliminari hanno mostrato che lo scaffold costituito da fibroina + 
dDPSCs è risultato essere l‘unico che maggiormente supporta il processo di 
osteogenesi/osteointegrazione nel sito di impianto, producendo matrice mineralizzata. 
Si può quindi concludere che, pur essendo ancora nella fase di risultati preliminari, gli 
scaffolds che meglio si integrano e favoriscono il processo di ossificazione, sono 
possibili supporti utilizzabili in medicina rigenerativa e come terapia tissutale al fine di 
sanare nei pazienti deficit scheletrici di diversa eziologia.  
 
In ultimo, analogamente allo studio sulle DPSC, si  sono isolate cellule staminali dalla 
placenta umana a termine, a seguito di digestione enzimatica e selezione mediante 
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MACS® per c-Kit. La placenta risulta essere una fonte di cellule staminali, ancora in 
fase di studio: si è quindi cercata una localizzazione  morfologica (nicchie) in sezioni di 
chorion incluse in paraffina, di cellule presentanti markers della linea germinale (Oct4 e 
Stella) e marker di staminalita‘(c-Kit). La localizzazione di nicchie di cellule staminali 
nella placenta ci permettere di selezionare una nuova fonte di cellule 
pluripotenti/multipotenti, da utilizzare nella terapia fetale o in utero, e nella medicina 
rigenerativa, utilizzando un tessuto  considerato ― di scarto‖, con potenzialità maggiori 
rispetto alle cellule adulte ma con minori problematiche etiche rispetto alle cellule 
germinali. 
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Introduction 
The Greek Titan, Prometheus, is a fitting symbol for 
regenerative medicine. As punishment for giving fire to 
Humankind, Zeus ordered Prometheus chained to a rock 
and sent an eagle to eat his liver each day. However, 
Prometheus' liver was able to regenerate itself daily, 
enabling him to survive. The scientific researchers and 
medical doctors of today hope to make the legendary concept of regeneration into 
reality by developing therapies to restore lost, damaged, or aging cells and tissues in 
the human body.  
 
Regenerative medicine  
The use of one body part for another or the exchange of parts from one person to 
another was mentioned in the medical literature even in antiquity and captured the 
imagination of many people over time. The maintenance of organs in culture was a 
major area of inquiry in the early 1900s. The kidney was the first entire organ to be 
replaced in human, in 1955 (Guilt WR.,1955); however, the lack of good immune-
suppression and the inability to monitor and control rejection, spurred physicians and 
scientists to look for other alternatives. Synthetic materials were introduced (like Teflon 
and silicone), opened a new field that included the use of devices for human use. 
However, the functional component of the original tissue was not achieved. Meanwhile, 
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new techniques for cell harvesting, culture, and expansion were developed: the concept 
of cell transplantation took hold in the research arena, and culminated with the first 
human bone marrow cell transplant in the 1970s. At this time, researchers began to 
combine the devices and materials with cell biology concepts, creating a new field 
called tissue engineering (Atala A  et al., 2009).  
In 1999, William Haseltine, the Scientific Founder and Chief Executive Officer of 
Human Genome Sciences, coined the term ‗regenerative medicine’,(Haseltine et al., 
1999): a new branch of medicine will develop that attempts to change the course of 
chronic disease and in many instances will regenerate tired and failing organ systems. 
Regenerative medicine brings all these areas (tissue engineering, cell transplantation, 
stem cells), under one defining field.  In the last two decades, scientists have attempted 
to grow native and stem cells, engineered tissues, and to design treatment modalities 
using regenerative medicine techniques virtually for every tissue of the human body.  
Applications of regenerative medicine technology may offer novel therapies for patients 
with injuries, end-stage organ failure, or other clinical problems, and may resolve the 
severe shortage of donor organs that is worsening yearly as the population ages as well 
as the increase of new cases of organ failure. Scientists in the field of regenerative 
medicine and tissue engineering are now applying the principles of cell transplantation, 
material science, and bioengineering to construct biological substitutes that will restore 
and maintain normal function in diseased and injured tissues. The stem cells field is also 
advancing rapidly, opening new avenues for this type of therapy (Atala A et al., 2009). 
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Cells for use in regenerative medicine 
- Native cells  
Native cells used for tissue engineering are obtained from a small biopsy of tissue. 
When native cells are used for tissue reconstitution, donor tissue is dissociated into 
single cells, which are implanted directly into the host or expanded in culture, attached 
to a support matrix, and reimplanted after expansion. The implanted tissue can be 
heterologous, allogenic (donor derived) or autologous (the host‘s cells). Ideally, 
―autologous approach‖ allows lost tissue function to be restored or replaced in toto and 
with limited complications (Atala A et al., 1997); autologous cells are not rejected by 
the immune system, and the use of immunosuppressant drugs is avoided.  Native cells 
and tissues are usually preferable for reconstruction. In most cases, the replacement of 
lost or deficient tissues with functionally equivalent cells and tissues would improve the 
outcome for these patients. An advantage in using native cells is that they can be 
obtained from the specific organ to be regenerated, expanded, and used in the same 
patient without rejection, in an autologous manner. Bladder, ureter, and renal pelvis 
cells can be equally harvested, cultured, and expanded in a similar fashion (Cilento BG 
et al., 1994; Liebert M et al., 1997; Atala A et al., 1993). 
However, one of the limitations of applying cell-based regenerative medicine 
techniques to organ replacement has been the inherent difficulty of growing specific cell 
types in large quantities. Even when some organs, such as the liver, have a high 
regenerative capacity in vivo, cell growth and expansion in vitro may be difficult. By 
noting the location of the progenitor cells, as well as by exploring the conditions that 
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promote differentiation and/or self-renewal, it has been possible to overcome some of 
the obstacles that limit cell expansion in vitro (Atala A,  2009). Major advances in cell 
culture techniques have been made during the past decade, and these techniques make 
the use of autologous cells possible for clinical application. However, even now, not all 
human cells can be grown or expanded in vitro. Liver, nerve, and pancreas are examples 
of human tissues where the technology is not yet advanced to the point where these cells 
can be grown and expanded. Native cells and tissues are usually preferable for 
reconstruction. Furthermore, autologous cells are recognized as the ideal transplantation 
resource, some patients with end-stage organ disease or with not functioning organ 
because of congenital or acquired diseases, do not produce enough cells for 
transplantation. In these situations, allogenic cells may be advantageous: 
pluripotent/multipotent stem cells are envisioned as an alternative source of cells from 
which the desired tissue can be derived.  
 
- Stem cells 
 ‗‗Stem cells are defined as clonogenic, self-renewing progenitor cells that can generate 
one or more specialized cell types‘‘ (Anderson et al., 2001; also defined in Potten and 
Loeffler, 1990). The term ‗‗stem cell‘‘ can be traced back to the late 19th century, 
where it was primarily used to describe what are today called the germline stem cells 
(Haeckel, E., 1877; Ramalho-Santos M  and Willenbring, H, 2007). Later, the term was 
used to describe stem cells of the hematopoietic system (Till JE et al., 1961). Now, the 
identification of stem cells has progressed beyond embryologic systems and  was found 
in almost every adult tissue.  Stem cells are undifferentiated cells with the capacity to 
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self-renew, differentiate and repopulate a host in vivo (Kuhn NZ et al., 2009). 
Regardless of their tissue of origin, human stem cells can be more broadly organized 
into a hierarchy based on their ontogenetic origin. Their plasticity or potency is ranging 
from: 
a) totipotent (differentiating into all cell types including placenta), 
b)  pluripotent (differentiating into cells of the three germ layers, ectoderm, 
mesoderm and endoderm, but not trophoblastic cells),  
c) multipotent (differentiating into cells of more than one type but not necessarily 
into all the cells of a given germ layer) ,  
d) unipotent (differentiating into one type of cell only, e.g. muscle or neuron).   
During mammalian development, the fertilized oocyte generates a complex organism 
comprising more than 200 different cell types. This developmental potential results 
from the capability of early embryonic cells to proliferate and to differentiate into all 
cell lineages including the germ line. ‗Totipotency‘, defined as the ability to generate an 
entire organism independently, is retained by the zygote and its early progeny up to the 
8-cell stage of the morula (Fig. 1).  
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Thereafter, primary cell differentiation processes result in the formation of blastocyst 
composed of outer cells forming the trophoblast, whereas the inner cells, known as the 
‗inner cell mass‘ (ICM), remain undifferentiated. The cells of the ICM are no longer 
totipotent, but retain the ability to develop into all cell types of the embryo proper. The 
ICM cells of mouse embryos have been cultured in vitro as undifferentiated embryonic 
stem (ES) cell lines with no apparent loss of potential (Czyz J et al., 2003).  
Pluripotent stem cells can be derived from the inner cell mass of the pre-implantation 
embryo (i.e. embryonic stem (ES) cells) or isolated from the foetal primordial germ cell 
pool (PGC) above the allantoids (i.e. embryonic germ (EG) cells and embryonic 
carcinoma (EC) cells; Thomson, JA., et al.,. 1998). The destruction of the blastocyst or 
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early fetus necessary for their derivation/isolation raises ethical concerns, although 
recent work has shown that ES cells can be derived from single blastomeres isolated 
using procedures similar to those routinely used for pre-implantation genetic diagnosis. 
However, safety concerns remain because of the tumorigenicity of ES cells. The 
subsequent establishment of human embryonic stem (hES), and embryonic germ (hEG; 
Shamblott, MJ et al., 1998) cells has evoked widespread discussion concerning the 
potential application of human embryonic stem cells in regenerative medicine. This 
debate has been enlivened further by a series of reports that stem cells continue to reside 
in various tissues and organs throughout the life of an organism, and that at least some 
of these ‗adult stem‘ (AS) cells may cross lineage boundaries to generate a variety of 
tissue types.   
Adult stem cells can be found in almost all tissues examined, including brain, dental 
pulp, muscle, bone marrow, skin and pancreas and have been extensively characterized 
for their therapeutic potential. The adult stem cell could be multipotent, capable to 
differentiate in cells that belong to the same germ layer (e.g. hematopoietic stem cells 
(HSCs) giving rise to all blood cells and adherent stromal/mesenchymal stem cells 
(MSCs) that give rise to bone, fat, cartilage and muscle), or unipotent (e.g. progenitor 
cells),  with limited capacity of self-renewal, that can differentiate only in one cell type.  
Stem cells: Embryonic-adult-foetal 
- Embryonic stem cells  
In 1981 pluripotent cells were found in the inner cell mass of the human embryo, and 
the term ‗human embryonic stem cell‘ (hESC) was coined (Martin GR et al., 1981).  
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ESCs are generally isolated from the inner cell masses (ICMs) of blastocysts (five days 
post fertilization), which consist of pluripotent cell populations that are able to generate 
the primitive ectoderm during embryogenesis (Fig. 2). More specifically, in normal 
embryonic development, the primitive ectoderm gives rise during the gastrulating 
process to the primary germ layers, including ectoderm, mesoderm, and endoderm. 
These three germ layers might subsequently generate a variety of organized tissue 
structures involving complex epithelial- mesenchymal interactions (Mimeault M et al., 
2006).  
ESCs are defined by their unique capacity to self-renew indefinitely in cell culture, 
long telomere length (high levels of telomerase expression), high nuclear/cytoplasmatic 
ratio, and demonstrate an unparalleled differentiation capacity. In this matter, ESCs 
possess the dual ability to undergo unlimited self-renewal and to differentiate in all 
foetal and adult stem cells and their more differentiated progenitors (Nelson TJ  et al., 
2009). Recent reports have shown that: 
- skin and neurons have been formed, indicating ectodermal differentiation 
(Reubinoff BE et al., 2001); 
-  blood, cardiac cells, cartilage, endothelial cells, and muscle have been formed, 
indicating mesodermal differentiation (Kaufman DS et al., 2001); 
- Pancreatic cells have been formed, indicating endodermal differentiation 
(Assady S et al., 2001).  
These cells have demonstrated longevity in culture by maintaining their 
undifferentiated state for at least 80 passages when grown using current published 
protocols (Reubinoff BE et al., 2000) and lineage specific differentiation of ESCs 
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can be directed under specific culture conditions and by manipulating  the 
microenvironment (Hwang WS et al., 2005).  
 
A potential limitation of ESCs with regard to regenerative applications relates to their 
inherent unrestricted growth potential with the associated risk of teratoma formation 
prominent once differentiation cues are evaded following transplantation. Given these 
considerations, therapeutic applications of ESC have so far been limited to preclinical 
studies (neurological disorders, such as Parkinson‘s disease, endocrine disorders, such 
as Type I diabetes, liver and renal failure, spinal cord injuries.). Their clinical 
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application is also limited because they represent an allogenic resource and thus have 
the potential to evoke an immune response (Hipp J et al., 2008).  
Human ESCs are also inherently connected to ethical issues because of their origin in a 
blastocyst, and the potential that the technology can be used to clone human beings. The 
International Society for Stem Cell Research has published ethical guidelines for human 
ESC research (Daley GQ et al., 2008). To date, researchers should retain open 
communication with the public and policy makers with regard to the direction to be 
taken concerning stem cell- based therapies. 
- Embryo Bodies 
As further evidence of their pluripotency, when cultured in suspension without anti-
differentiation factors, ES cells spontaneously differentiated in vitro and formed three-
dimensional multi-cellular aggregates called Embryo Bodies (EBs). An EB consists of 
ectodermal, mesodermal, and endodermal tissues, which recapitulate many aspects of 
cell differentiation during early mammalian embryogenesis (Itskovitz-Eldor J et al., 
2000). As differentiation continues, a wide range of cell types is developed within the 
EBs environment (Zhou J et al., 2010). Therefore, EBs formation has been widely 
utilized as a trigger during the process of ES cells differentiation in vitro. Because of the 
important role the EBs played in the in vitro differentiation system of ES cells, the 
quality of EBs formed from ES cells affects the induction efficiency of derivatives from 
the EBs in a subsequent differentiation culture (Koike M et al., 2007). The partial 
disaggregating and subculture of EBs might allow the isolation and differentiation of a 
particular progenitor cell type that might be isolated on the basis of the expression of 
specific cellular markers. More particularly, the use of specific growth factors or 
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cytokines during the outgrowth of EBs in culture in vitro might induce their 
differentiation into the specific cell lineages (Fig. 3). One of the critical steps in the 
purification procedure appears to be the enrichment of EB-derived progenitor cells by 
the elimination of pluripotent and undifferentiated stem cells. Indeed, the elimination of 
undifferentiated stem cells that may form teratomas or teratocarcinomas in vivo appears 
to be essential for generating transplantable sources of differentiated stem cell 
progenitors for the treatment of diverse disorders. Therefore, they represent a useful 
source of stem cells for investigating the molecular events that are involved in normal 
embryogenesis and generating a large number of specific differentiated progenitors for 
cellular therapies. 
 
 
 
 
 
 
- Markers of hESC   
Embryonic stem cell phenotype has been studied in detail and several markers have 
been reported as ESC specific antigens, including transcription factors Oct4, Nanog, 
Sox2, cell surface antigen SSEA-4, Stella and others (Adewumi O et al., 2007). For 
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characterization of hESCs, it is common to report one or more of the following: Oct4 
expression, alkaline phosphatase and telomerase activities; stage-specific embryonic 
antigens 3 and 4; hESC antigens TRA-1–60, TRA-1–81, GCTM-2, TG-30, and TG-343; 
and CD9, Thy1, and major histocompatibility complex class 1 (MHC-1) (Stojkovic M 
et al., 2004). Other stem cell antigens are also sometimes reported, e.g., AC133, c-kit 
(CD117), and flt3 (CD135), but these are frequently only expressed in a proportion of 
the hESC population, making them potential derivatives of interest in the heterogeneous 
hESC cell population. Oct-4 (octamer-binding transcription factor 4) also known as 
POU5F1 (POU domain, class 5, transcription factor 1) is a protein that in humans is 
frequently used as a marker for undifferentiated cells. Oct-4 expression must be closely 
regulated; too much or too little will actually cause differentiation of the cells (Niwa H 
et al., 2000).  The transcription factor Oct4, coupled with Sox2, is a component of a 
network of transcription factors, including the homeobox protein Nanog, that 
cooperatively contribute to the maintenance of the undifferentiated state through 
fibroblast growth factor-4 (FGF-4), Wnt, and transforming growth factor- (TGF-) 
dependent pathway. Oct-4 transcription factor is initially active as a maternal factor in 
the oocyte but remains active in embryos throughout the preimplantation period. Its 
expression is associated with an undifferentiated phenotype and tumors (Looijenga L et 
al., 2003): in fact gene knockdown of Oct-4 promotes differentiation, thereby 
demonstrating a role for these factors in human embryonic stem cell self-renewal.  
Mouse embryos that are Oct-4-deficient or have low expression levels of Oct-4 fail to 
form the inner cell mass, lose pluripotency and differentiate into trophectoderm. 
Therefore, the Oct-4 expression level in mice is vital for regulating pluripotency and 
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early cell differentiation since one of its main functions is to keep the embryo from 
differentiating.Oct-4 has been implicated in tumorigenesis of adult germ cells. Ectopic 
expression of the factor in adult mice has been found to cause the formation of 
dysplastic lesions of the skin and intestine. The intestinal dysplasia resulted from an 
increase in progenitor cell population and the upregulation of β-catenin transcription 
through the inhibition of cellular differentiation (Hochedlinger K et al.,2005).  
Therefore, the presence of Oct4 expression alone may be misleading, as this 
transcription factor takes some time to shut down RNA transcription in differentiating 
hESCs and is also found in other pluripotent cell populations (e.g., embryonic germ 
stem cells), as well as some adult and foetal multipotential stem cells (Hoffman, LM., et 
al., 2005).  
Nanog is a transcription factor critically involved in self-renewal of undifferentiated 
embryonic stem cells. In humans, this protein is encoded by the NANOG gene (Mitsui K 
et al., 2003). Human Nanog protein is a 305 amino acid protein with a conserved 
homeodomain motif localized in the nuclear component of cells. NANOG is a gene 
expressed in ESCs and is thought to be a key factor in maintaining pluripotency. 
Overexpression of Nanog in mouse embryonic stem cells causes them to self-renew in 
the absence of Leukemia inhibitory factor (Lif); in the absence of Nanog, mouse 
embryonic stem cells differentiate into visceral/parietal endoderm: loss of its function 
causes differentiation into other cell types. In human embryonic stem cells, its 
overexpression enables their propagation for multiple passages during which the cells 
remain pluripotent. Gene knockdown of Nanog promotes differentiation, thereby 
demonstrating a role for these factors in human embryonic stem cell self-renewal. It has 
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been shown that the tumor suppressor p53 binds to the promoter of NANOG and 
suppresses its expression after DNA damage in mouse embryonic stem cells. P53 can 
thus induce differentiation of embryonic stem cells into other cell types, which undergo 
efficient p53-dependent cell-cycle arrest and apoptosis.  
Stella (Pgc7, Dppa3) is a maternal effect gene that encodes a protein with a SAP-like 
domain and a splicing factor motif-like structure and is specifically expressed in 
primordial germ cells, oocytes, preimplantation embryos and pluripotent cells (Payer B 
et al., 2003). The loss of maternally inherited Stella leads to a reduced fertility in Stella-
null females, while embryos devoid of Stella rarely develop to the blastocyst stage and 
are mainly blocked at the 2-cell stage (Payer B et al., 2003). It has been recently 
demonstrated that Stella, aside from localizing into the nucleus, also contributes to 
maintain the methylation state of several imprinted genes (Nakamura T et al., 2007). 
Stella, like all the other genes that localize within the Nanog locus, is co-regulated in the 
ES cells and the transcription factor Oct-4 regulates its expression, maintaining a higher 
order chromatin structure within this locus.  
- IPs 
Embryogenesis is a sequential process of differential gene expression dictated by the 
epigenetic environment. Exploiting epigenetic influence on phenotypic outcome, 
biotechnology platforms are developed for reversal of differentiation to achieve genetic 
reprogramming of adult sources back to embryonic state (Hochedlinger K et al., 2006). 
Recently, exciting reports of the successful transformation of adult cells into pluripotent 
stem cells have been published. Nuclear reprogramming is a technique that involves de-
differentiation of adult somatic cells to produce patient-specific pluripotent stem cells, 
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without the use of embryos, through ectopic introduction of a small number of 
pluripotency-associated transcription factors: Oct3-4, Sox2, Klf4 with (Yamanaka‘s 
group) or without (Thompson‘s group) the oncogene c-Myc and the transcription factor 
Nanog. Cells generated by reprogramming would be genetically identical to the somatic 
cells (and thus, the patient who donated these cells) and would not be rejected. 
Yamanaka was the first to discover that mouse embryonic fibroblasts (MEFs) and adult 
mouse fibroblasts could be reprogrammed into an ‗induced pluripotent state‘ (iPS). The 
resultant iPS cells possessed the immortal growth characteristics of self-renewing ES 
cells, expressed genes specific for ES cells, and generated embryoid bodies in vitro and 
teratomas in vivo. When iPS cells were injected into mouse blastocysts, they 
contributed to a variety of cell types. However, although iPS cells selected in this way 
were pluripotent, they were not identical to ES cells. Unlike ES cells, chimeras made 
from iPS cells did not result in full-term pregnancies. Gene expression profiles of the 
iPS cells showed that they possessed a distinct gene expression signature that was 
different from that of ES cells. In addition, the epigenetic state of the iPS cells was 
somewhere between that found in somatic cells and that found in ES cells, suggesting 
that the reprogramming was incomplete (Zhao HX et al., 2010).  
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- Adult stem cells 
Adult stem cells comprise a wide range of progenitors derived from non-embryonic, 
non-foetal tissue such as bone marrow, adipose tissue, and resident stem cells pools 
(Mimeault M et al., 2006). They are leading candidate for clinical application in 
regenerative medicine, based on accessibility autologous status, and favorable 
proliferative potential. Numerous studies have revealed that, a population of adult stem 
cells and supporting cells reside within specific areas designated as niches in most of 
adult mammalian tissues/organs, including BM, heart, kidneys, brain, skin, eyes, 
gastrointestinal tract, liver, pancreas, lungs, breast, ovaries, prostate, and testis (Fig. 5) 
(Modlin IM et al., 2003; Lavker RM et al., 2004; Li L et al., 2005; Griffiths  MJ et al., 
2005). In fact, adult stem cells appear for the first time during ontogeny and persist in 
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specialized niches within organs where they may remain quiescent for short or long 
periods. Although adult stem cells, as observed for ESCs, FSCs (Foetal Stem Cells), and 
UCB (Umbelical cord) stem cells, might exhibit an uncontrolled growth in a specific 
microenvironment and enhanced telomerase activity, they generally show a more 
restricted differentiation potential and give rise to a more limited number of distinct cell 
progenitors. Adult stem cells can notably undergo proliferation and differentiation into 
more mature and specialized tissue specific cell types following changes in their 
microenvironment within the niche. More specifically, stem cells and their supporting 
cells appear to interact reciprocally by forming diverse intercellular connections, such 
as gap and adherent junctions, for maintaining the niche integrity. Hence, latent adult 
stem cells appear to be activated during cell replenishment to repopulate the tissue 
compartments under physiological and pathological conditions (Fang D et al., 2005). 
During stem cell self-renewal, the expansion of each stem cell appears to involve its 
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symmetric division into two identical daughter stem cells. In contrast, the asymmetric 
division of stem cells during differentiation involves each stem cell dividing to produce 
one daughter stem cell and one daughter transit-amplifying (TA)/intermediate cell. The 
TA cells (TACs) that are generated during asymmetric division are generally 
characterized by a high proliferative index and migratory properties. The TACs may 
give rise to other intermediate cell progenitors and, ultimately, to more differentiated 
cells constituting tissues or organs where they originate or other, distant tissues. In fact, 
the migration of TACs to distant sites, as well as the changes in their local 
microenvironment during amplification, might be the basis of a population asymmetric 
division, which might result in the differentiation or trans-differentiation of TACs into 
different cell lineage progenitors (Fig.6) ( Alison MR et al., 2009).   
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In addition, many works have indicated that the adult stem cells, and more particularly 
BM stem cells, may be redistributed under certain physiological and pathological 
conditions to other distant tissues via circulation (Blau HM et al., 2001).  
Adult stem cells can be divided into 3 categories according to the germ layer from 
which they originate: 
 endodermal origin (pulmonary epithelial stem cells, gastrointestinal tract stem 
cells, pancreatic stem cells, hepatic oval cells, mammary and prostatic gland 
stem cells, and ovarian and testicular stem cells),  
  mesodermal  origin (bone marrow hematopoietic and stromal stem cells, and 
cardiac stem cells), 
  ectodermal (neural stem cells, skin stem cells, and ocular stem cells).  
These adult stem cells are also able to trans-differentiate in different mature cell 
lineages in vitro and in vivo (Choumerianou DM, 2008) .  
- Bone Marrow and Mesenchymal Stem Cells 
The most common source of adult stem cells is the bone marrow (Fig 7), a mesoderm 
derived well-organized tissue, composed of the basic elements from the stroma and the 
hematopoietic system, and located at the centre of large bones (Arai F et al., 2004). For 
decades, it has been known that the bone marrow contains two types of stem cells: 
hematopoietic stem cells (HSC), which are committed to differentiate into mature blood 
cells, and the less-differentiated stromal mesenchymal cells (MCs). The evidence of the 
presence of multipotent stem cells, was first reported in 1968 by Friedenstein and his 
colleagues by establishing that these cells are adherent, clonogenic and fibroblastic 
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(Friedenstein AJ et al 1968, 1974). For over 40 years, the stem cells from bone marrow 
(BM) have been denoted as a ‗colony forming unit fibroblast‘, ‗marrow stromal cells‘, 
or ‗mesenchymal progenitor cells‘ in published literature. Currently they are called 
„mesenchymal stem cells‟ (MSCs), which are defined as cells that can differentiate 
into multiple mesenchymal lineage cells (Phinney DG, 2002; Pittenger MF et al., 1999), 
a notable exception to the tissue specificity of adult stem cell. MSCs contribute to the 
regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligaments, 
tendons, adipose and stroma (Caplan AI, 2005).To date, bone marrow stem cells are the 
most frequently used cell source for bone tissue engineering (Seong JM et al., 2010) . 
  
Ever since the emergence of the MSC, cells with MSC-like characteristics have been 
identified in not only mesoderm derived, but also endoderm- and ectoderm-derived 
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tissues (Fig. 8). Examples of tissues where MSCs have been characterized include, but 
are not limited to: mesodermal— bone marrow, trabecular bone, synovium, cartilage, 
fat, muscle, and tonsil, endodermal—thymus, ectodermal—skin, hair follicle, dura 
mater, and dental pulp (mesoderm and ectoderm-derived), prenatal and perinatal 
tissues—umbilical cord, umbilical cord blood, and placenta (Kunh NZ et al., 2009). 
 
Although still controversial, literature exists demonstrating the potential of MSCs to 
differentiate along non-mesodermal lineages such as ectodermal skin and neurons and 
endodermal hepatocytes. MSCs are still correctly defined as ‗‗multipotent,‘‘ rather than 
‗‗pluripotent,‘‘ despite these reports of their potential capability to differentiate into 
derivatives of all three germ layers. The ultimate test for pluripotency is tetraploid 
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complementation where stem cells injected into the mouse blastocyst generate germ-
line competent chimeric mice (Kunh NZ et al., 2009). 
- Surface marker characterization of mesenchymal stem cells  
MSCs isolated from human bone marrow and other mesenchymal tissues must 
demonstrate in vitro:  
  adherence to plastic in standard culture conditions, 
 specific surface antigen expression,   
 multipotent differentiation potential along the osteogenic, chondrogenic, and 
adipogenic lineages as demonstrated by histological staining and other methods. 
Identification of adult human mesenchymal stem cells as multilineage progenitors relies 
on their capacity to be induced to differentiate into specific phenotypes. Although the 
ganglioside GD2 has been proposed as a single surface marker that distinguishes 
mesenchymal stem cells, a panel of biomarkers has been typically employed to secure 
isolation. BM-MSCs have been found to be positive for a variety of markers, such as 
STRO-1(Simmons and Torok-Storb,1991; Gronthos S et al.,., 1994), CD105 (endoglin), 
SH3, CD29, CD44, CD71, CD90(Thy-1), CD106, CD120a, CD124, and other surface 
proteins (Pittenger MF et al., 1999).The consensus of ―The International Society for 
Cellular Therapy (ISCT)‖, which is subject to future modification, is that measurements 
by flow cytometry show  that  no more than 2% of the cells may express CD34 
(hematopoietic progenitor and endothelial cell marker), CD45 (pan-leukocyte marker), 
CD11b or CD14 (monocyte and macrophage markers), CD19 or CD79a (B cell 
markers), and HLA-DR (marker of stimulated MSCs). 
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Dental pulp stem cells (DPSCs) 
Since the discovery and characterization of multipotent mesenchymal stem cells 
(MSCs) from bone marrow (BM), MSC-like populations from other tissues have now 
been characterized based on the ‗gold standard‘ criteria established for BMMSCs 
(Friedenstein AJ et al.,., 1976; Caplan AI,1991; Prockop DJ,1997; Pittenger MF et al., 
1999; Gronthos S et al., 2003). The search for MSC-like cells in specific tissues has led 
to the discovery of a variety of stem cells in every organ and tissue in the body in the 
past decades (Kolf C et al.,2007) like human muscle and adipose tissue. However, more 
easily available alternative sources of cells expressing an ability to differentiate and to 
modulate the immune response are badly needed (Huang GTJ et al., 2009). A promising 
source is dental pulp (Fig 9-10), a loose vascular connective tissue surrounded by 
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dentine and consisting of a heterogeneous population of cells: the potential 
preodontoblast, fibroblasts, stromal cells, endothelial and perivascular cells, neural cells 
and others (Pierdomenico L et al., 2005). Dental-tissue-derived MSC-like populations 
are cells residing in this specialized tissue that have been isolated and characterized. 
The first type of dental stem cell was isolated from the human pulp tissue and termed 
‗postnatal dental pulp stem cells‘ (DPSCs) (Gronthos S et al., 2000). Subsequently, 3 
more types of dental-MSC-like populations were isolated and characterized: stem cells 
from exfoliated deciduous teeth (SHED) (Miura M et al., 2003), periodontal ligament 
stem cells (PDLSCs), and stem cells from apical papilla (SCAP) (Sonoyama W et al., 
2006, 2008). Recent studies have identified a fifth dental tissue-derived progenitor cell 
population, referred to as ‗dental follicle precursor cells‘ (DFPCs) (Morsczeck C et al., 
2005). Recently, several groups have initiated investigation of this potential source and 
have begun to examine the properties of stem cells isolated from dental pulp. 
(Nakashima M, 2009) Stem cells extracted from the pulp of the not-erupted third molar 
(Fig.10) have some advantages for clinical applications compared with other 
mesenchymal stem cells derived from bone marrow, adipose tissue, peripheral blood, 
and umbilical cord blood.  
- Easy surgical access and low invasiveness. 
- Very low morbidity of the anatomical site after the collection of the pulp.  
-  High efficiency of the extraction procedure of the stem cells from the pulp 
tissue. 
In fact, according to the ISTAT data in 2008, 30.2 million (equal to 60.1%) Italian 
citizens have at least one tooth extracted, whereas people with five teeth extracted or 
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fallen are 1.9 million people. Therefore, the extraction, from healthy subjects, of one or 
more molars seems to be quite 
widespread among the population.  
 Minimal tooth processing 
may be needed for the 
banking of samples with no 
immediate plans for DPSC 
expansion and use, which in 
turn may limit costs and 
facilitate clinical banking of 
this potentially important cell 
type. 
Stem cells obtained from any adult 
tissue are less, about 1-4%. Further, 
their isolation, expansion, and storage is a very technique-sensitive procedure.  
 Cryopreservation. 
Cells expanded in culture are readily preserved and can be stored for at least six months 
and likely longer at −85°C with respect to qualitative ability to differentiate in at least a 
tri-lineage manner. So they can be cryopreserved, retaining multi-differentiation 
capacity (Graziano A. et al., 2008). 
 They do not form teratoma in vivo. 
  High differentiation ability. 
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They are highly clonogenic, showing a high proliferation potential and are able to self-
maintain for long time (Laino G  et al., 2005).  
- DP-MSCs inhibit the proliferation of phytohemagglutinin (PHA) stimulated T-
cells and the effect being stronger than in BM-MSC.( Pierdomenico L  et al., 
2005)  
The rapid proliferative kinetics of DP-MSC, as compared to their bone marrow 
counterparts, might represent an immunosuppressive advantage when treating immune 
reactions, such as graft-versus-host disease, in view of their potentially greater effect. 
Therefore, dental pulp-MSCs may prompt future studies aimed at using these cells in 
the treatment or prevention of T-cell alloreactivity in hematopoietic or solid organ 
allogeneic transplantation.  
- MSC populations are considered immunomodulatory as they lack MHC type II 
(major histocompatibility complex) antigen and therefore do not provoke 
immune reactions.  
As of now, autologous stem cells are ideally suited for a patient as there is no risk of 
immune rejection, the process is least expensive, and avoids legal and ethical concerns: 
there are many in vivo studies which support that they are immunologically safe. 
- Up to now, in trauma and reconstructive surgery, DPSCs can be used in 
combination with biomaterials in the treatment of critical size bone defects, 
which are too large to be repaired by endogenous repair mechanisms. (Wenish S 
et al., 2006) 
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- Tooth morphogenesis( origin of dental pulp) 
During the sixth week of embryogenesis, after the migration of neural crest cells into 
head and neck mesenchyme, the ectoderm covering the stomodeum begins to 
proliferate, giving rise to the dental laminae. From the dental lamina, following ecto-
mesodermic interactions, ovoidal structures start to separate and then develop into tooth 
germs, where neural crest cells differentiate into the dental organ, dental papilla and 
dental follicle, forming the main part of the dental and periodontal structures. 
Therefore, dental pulp is made of both ectodermic and mesenchymal components, 
containing neural crest cells that display plasticity and multipotential capability. 
After crown mineralization, dental pulp tooth germ remains entrapped within a hard 
structure that preserves it from environmental differentiation stimuli (D‘Aquino R et al., 
2006). 
The pulp is divided into four layers, from the outer to the inner part: (1) the external 
layer made up of odontoblast producing dentin; (2) the second layer, called ―cell free 
zone‖, poor in cells an rich in extracellular matrix; (3) the third layer, called ―cell rich 
zone‖, containing progenitor cells that display plasticity and pluripotential capabilities, 
like DPSCs (Sinanan AC et al., 2004); 4) the inner layer, that comprises the vascular 
area and nervous plexus.  
After the crown eruption the dental pulp, remains entrapped within the pulp chamber, a 
sort of ―sealed niche‖ and may explain that it is possible to find, within it, a pretty large 
number of stem cells although in an adult tissue. In the case of the third molar, the 
development begins at the sixth year of life: it means that until this time, embryonic 
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tissues from dental lamina remain quiescent and undifferentiated within the jaws, the 
only organogenesis event that completely occurs after the birth. 
-DPSCs 
DPSCs usually remain quiescent within adult dental pulps, but respond during injury to 
produce progenies with high proliferative potential, which can differentiate into 
terminally differentiated odontoblasts.  
As a type of adult stem cells, DPSCs usually perform the asymmetric cell division, 
which gives rise to one daughter cell with stem-cell fate and another which can pursue 
further cell divisions to generate differentiated progenies (Gronthos S et al., 2002, 
Huang GT-J et al., 2009). Thus, the amount of DPSCs in the normal dental pulp 
remains relatively constant. When one DPSC divide 9 times, it will generate 9 lineage-
specific progeny cells plus one unaltered daughter stem cell. These lineage-specific 
progenies in vivo may bring about different cell types, which contribute to the 
maintenance and homeostasis of dental pulp tissues (Yu J et al., 2010). 
Although dental tissues are specialized tissues that do not undergo continuous 
remodeling, as shown in bone tissue, many studies have demonstrated that DPSCs have 
the ability to undertake the self-renewal and the multi-differentiation capacity. DPSCs 
can be isolated from digested pulp tissue, with a colony selection or an 
immunomagnetic isolation method (MACS) and cultured in different inductive media 
(Seong JM., 2010). They display clonogenic and highly proliferative characteristics, and 
they can differentiate into the neurogenic, osteogenic, dentinogenic, and myogenic cell 
lineages (Zhang W et al., 2006).   
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To date, there is no optimal culture medium that can allow adult stem cell amplification 
without differentiation (D‘Aquino R. et al., 2007). It is reasonable that native DPSCs in 
vitro can spontaneously differentiate (termed self-differentiation) into mature cell 
lineages via asymmetric cell division, as reported in the paper of Yu et al., (2010): the 
differentiation capacity of these stem cells change during cell passaging and DPSCs 
restrict their differentiation potential to osteoblast lineages. 
Previous studies have demonstrated that DPSCs are able to  differentiate into 
CD44+/RUNX-2+ osteoblast precursors and then into osteoblasts in α-MEM 
containing 20% FBS, ascorbic acid- 2-phosphate, and L-glutamine. For tissue 
engineering approach, in order to produce new –formed bone, we need to select and 
define a clonal subset of stem/progenitor cells particularly able to differentiate in the 
osteogenic lineage after culture in a specific osteogenic medium.  
This sub-population of Stromal Bone Producing-DPSC, named SBP-DPSCs, was 
isolated from DPSCs using immunoselection of c-Kit, CD34 and STRO-1 antigen 
markers by flow cytometry and magnetic-activated cells sorting (Papaccio G et al., 
2006). 
 
- Markers 
C-kit is a membrane tyrosin-kinase III receptor, product of the c-Kit proto-oncogene, 
which specifically binds the stem cell factor (SCF) (Thomas ML, 1989). In human adult 
it is expressed by the cells of the so called ―side populations‖, resident in several tissues. 
Typically, SCF and c-Kit are expressed by different cells in the same 
microenvironment; i.e. SCF is secreted by bone marrow stromal cells and supports 
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hematopoietic cells survival and proliferation. Of relevance, c-Kit is expressed in neural 
crest-derived stem cells, like melanocyte precursors (Garcia-Pacheco JM et al., 2001), 
and cells deriving from neural crest progenitors, like dental pulp cells. In DPSCs c-kit is 
highly end early expressed and its presence could be attributed to the ectomesenchymal 
origin of these cells.  
In the craniofacial region, it has been used to identify multipotent stem cells (Sinanan, 
AC et al., 2004) however after differentiation into lineage-committed progenitors, c-Kit 
is gradually lost (Simmons & Torok-Storb, 1991). 
CD34 is a single-chain transmembrane glycoprotein expressed on human 
haematopoietic stem and mesenchymal progenitor cells: it is a marker for primitive 
pluripotential stem cells both stromal and hematopoietic. Although it is currently used 
in clinical applications of stem cell therapy with cells of hematopoietic origin,  its 
presence is not detectable in mesenchymal stem cells from bone marrow (Liu L et al., 
2006; Lee SY et al., 2007) and its expression in bone marrow stem cell-derived bone 
progenitors has not been definitively demonstrated (Sinanan AC  et al., 2004). However 
it must be considered that in mesenchymal stem cell, CD34 expression might be 
detectable from different sources such as adipose tissue (Yoshimura K et al., 2006), and 
by other cell types, such as the mesangioblasts, that can give rise to bone progenitors 
too (Yoshimura K et al., 2006). In previous studies, it has been demonstrated that 
CD34, in association with CD117, can be used to select a population of dental pulp stem 
cells able to differentiate into pre-osteoblasts in vitro (Laino G.et al.,2005, 2006).  
STRO-1 recognizes a trypsin-resistant cell-surface antigen of perivascular cells and is 
thought to be a putative cell surface marker for the isolation of stem cells from human 
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dental pulp.  This cell surface antigen is present on precursors of various stromal cell 
types, including marrow fibroblasts, osteoblasts, chondrocytes, adipocytes, and smooth 
muscle cells isolated from adult and foetal bone marrow (Simmons TJ Torok-Storb 
1991; Gronthos S et al., 1994).  Yu et al., (2010) suggest that STRO-1
+
DPSCs consist 
of at least three interrelated subpopulations including the progenitors of odontoblasts, 
osteoblasts, and chondrocytes, which can form dentin, bone, and cartilage tissues 
respectively. 
Previous studies have implicated STRO-1 as a marker of preosteogenic populations, 
where its expression is progressively lost after cell proliferation and differentiation into 
mature osteoblasts in vitro (Stewart K et al.,  1999). The STRO-1 antigen was also 
found to be present on the outer cell walls of human bone marrow and dental pulp blood 
vessels, in agreement with previous studies that localized STRO-1 on large blood 
vessels, but not capillaries, in different adult tissues such as brain, gut, heart, kidney, 
liver, lung, lymph node, muscle, and thymus. (Bianco P et al., 2001). Therefore, STRO-
1 seems to be an early marker of different mesenchymal stem cell populations and 
infers a possible perivascular niche for these stem cell populations in situ. 
For all of these reasons, CD34, STRO-1 and c-Kit expression, identify a population of 
mesenchymal stem cells of neural crest origin (Laino G et al., 2006). 
  
- DPSCs osteogenic differentiations 
Both osteogenic and angiogenic cytotypes can be found in the human dental pulp stem 
cell (CD34
+
/c-Kit
+
/STRO-1
+) population (D‘Aquino R et al., 2007); however to 
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promote and to enhance the osteoblastic-differentiation in vitro an osteogenic medium is 
necessary. 
The osteogenic differentiations is induced by Dexamethasone, Ascorbic acid and -
Glycerophosphate in culture media (Jager M et al., 2005), also called DAG osteoblastic-
supplements. 
Ascorbic Acid (AA; reduced vitamin C) is an essential cofactor for osteoblast 
differentiation both in vivo and in vitro and it is necessary for expression of the 
osteoblast phenotype (Franceschi RT, 1992). Actions of AA on osteoblast 
differentiation require the synthesis of a collagenous extracellular matrix (ECM) and 
may be mediated by integrin: matrix interactions. Before it can function, this vitamin 
must be transported into cells via aspecific Na
+
-dependent AA transporter (Wilson and 
Dixon, 1989). Osteoblasts
 
contain a specific Na
+
-dependent AA transport system that is
 
essential for the intracellular accumulation of vitamin C and
 
cellular responsiveness 
(Pandipati S et al., 1998). In primary cultures of osteoblast-like
 
cells or no transformed 
osteoblast-like cell lines (such
 
as murine MC3T3-E1 cells) (Franceschi RT, 1994), AA 
stimulates pro-collagen hydroxylation,
 
processing, and fibril assembly followed by a 
dramatic induction
 
of specific genes associated with the osteoblast phenotype including
 
those encoding osteocalcin, alkaline phosphatase, bone sialoprotein,
 
and the PTH/PTH-
related protein receptor. Furthermore, induction
 
of gene expression by AA is 
specifically and reversibly blocked
 
by inhibitors of collagen matrix formation or 
purified bacterial
 
collagenase. Thus, studies with AA strongly support a model
 
in which 
expression of the osteoblast phenotype is profoundly affected
 
by the extracellular matrix 
(ECM).  
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To date AA is necessary for osteoblastic production of collagen and enhances alcaline-
phosphatase (AP) activity and it has been shown to decrease cellular proliferation, 
possibly acting as one of the signals postulated to be necessary for progression from 
proliferation phase to the matrix maturation phase (Lian JB et al., 1997). 
Glucocorticoids, i.e. dexamethasone, are potent stimulators of in vitro osteoblastic 
differentiation in bone marrow stromal osteoprogenitors (Bellows CG et al., 1987), in 
mesenchimal stem cells and other cells types (Jager M et al., 2005). Dexamethasone, a 
synthetic glucocorticoids, acts by stimulating the expansion, the differentiation, the gene 
expression and the synthesis of ECM of osteoprogenitors presents in these mixed 
population (IshidaY et al.,1996). The glucocorticoid-dependent-up-regulation of AA 
transport represents an appropriate response to allow maximal induction of osteoblast 
differentiation, because, AA-dependent collagen matrix synthesis is necessary, for 
subsequent expression of osteoblast-related genes (Franceschi RT, 1992) and osteoblast 
precursors must have an active Na
+
-dependent AA transporter to respond to vitamin C. 
The extracellular matrix (ECM) of bone contains important structural and soluble 
factors required for its development and morphogenesis, i.e. type I collagen (Mizuno H 
et al., 2002) and the interactions of collagen with integrins enhance the gene expression 
of the osteoblastic markers alkaline phosphatase (AP), osteocalcin (OC), and bone 
sialoprotein (BSP). Dexamethasone promotes osteoblast differentiation and 
development of bone tissue like organization in cultured osteoblasts by accelerating the 
developmental sequence of cell growth and bone related genes expression resulting in 
increased formation of mineralized bone nodules.   
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Moreover, dexamethasone modulates the osteoblastic phenotype in vitro and influences 
the migration and the proliferation of MSCs. Several authors empathize the proliferative 
effects of dexamethasone in bone precursor cells and osteoblast, but Walsh S et al., 
(2001) reported dose-dependent inhibitory effect on bone marrow cells in vitro. They 
showed that supra-physiological dexamethasone concentrations above 10
-9
 M are 
associated with a decrease in the median diameter of CFU, but promote the 
differentiation or further maturation of human osteoblast precursors in human DPSCs 
and bone marrow cells cultures.   
Beta-glycerophosphate (GP) is a disodium salt hydrate. It has been shown in several 
laboratories that addition of GP, as a phosphate source and substrate for alkaline 
phosphatase (AP), to cultured osteoblast-like cells induces deposition of orthophosphate 
(Pi) and Ca
2+
 (Deliloglu Gurhan SI et al., 2005). Using cultures continuously exposed to 
GP during the bone formation stage, Tenenbaum HC et al.,(McCulloch CAG et al., 
1989) also reported an increase in alkaline phosphatase activity coincident with or just 
before the onset of mineralization. 
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- Osteogenic differentiation : physiological context 
A brief introduction about osteoblast differentiation and maturation occurring in 
physiological context is helpful to better understand how DPSCs can differentiate into 
osteoblast precursors and then into mature osteoblasts in vitro and in vivo, under 
specific stimuli.  
Bone formation is a tightly regulated process that involves four distinct phases: 
1. Migration of mesenchymal cells with osteogenic potential to the site of future 
skeletogenesis, 
2. Mesenchymal-epithelial interactions, 
3. Condensation (or aggregation) of mesenchymal cells,  
4. Differentiation into the osteogenic lineage (Heng BC et al., 2004). 
After the recruitment of mesenchymal cells, it is characterized by a sequence of events 
starting with the commitment of osteoprogenitor cells, their differentiation into pre-
osteoblasts and in mature osteoblasts whose function is to synthesize the bone matrix 
that become progressively mineralized. Osteoblast (polyhedral mesenchymal cell 
responsible for synthesizing new bone matrix) commitment, differentiation and function 
are all governed by several transcription factors, resulting in expression of phenotypic 
genes and acquisition of the osteoblast phenotype (Marie PJ et al., 2008). All the steps 
of the lineage determinations, are a multiple-step series of events modulated by an 
integrated cascade of gene expression that initially supports a proliferation phase, then 
the sequential expression of genes associated with the biosynthesis, organization and  
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mineralization of the bone extracellular matrix , that characterize the matrix maturation 
phase and the mineralization phase. In 1986, Bellows and his colleagues developed a 
method to culture normal diploid calvarial-derived osteoblast under conditions that 
support development of a tissue like organization similar to embryonic bone and 
provided a variable in vitro model system for experimentally addressing the osteoblast 
proliferation/differentiation relationship within the context of physiological regulation. 
The tissue-like organization in vitro is reflected by the progressive development of 
nodules of multilayered cells and mineralized extracellular matrix with organized type I 
collagen fibrils. The ordered deposit of minerals within the collagen fibrils initiates and 
is primarily associated with the nodular area. The sequential expression of cell growth 
and tissue-specific gene defines three distinct developmental periods as shown in Figure 
11.  
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The growth (proliferation) period is reflected by increase of osteoblast cell population 
with expression of cell cycle (e.g. histones, cyclines) and cell growth regulated genes 
(e.g. c-myc, c-fos, c-jun). At the same time several genes associated with formation of 
extracellular matrix [type I collagen (Col I), fibronectin and transforming growth factor-
 (TGF-)] are actively expressed. 
The second period initiates following the down regulation of proliferation where 
expression of the genes associated with maturation and organization of bone 
extracellular matrix are up-regulated. These later genes contribute to rendering the ECM 
competent for mineralization. 
The third developmental period reflects mineralized cultures in which other bone related 
genes are induced, e.g. bone sialoprotein (Nagata, T., et al., 1991), Osteopontin (OPN) 
and Osteocalcin (OCN) levels are increased, paralleling the accumulation of mineral. 
OCN levels increase 100-fold when maturation of bone-tissue like organization is 
ongoing: the maximal level of expression observed with the mineralization of 
extracellular matrix is similar both in vivo and in in vitro. 
The high expression of OCN during the later stage of osteoblast development sequence 
makes it a marker for mature osteoblast phenotype. As the mineralization proceeds, 
alkaline phosphatase mRNA declines and OCN mRNA levels become down regulated 
in heavily mineralized cultures.  
The mineralization period is followed by the appearance of apoptotic cells along with 
the mineralized nodule; during this period, collagenase and type I collagen gene 
expression increase and may be involved in the collagen turnover associated with 
reorganization of the collagen matrix. These events have suggested to serve a 
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remodeling function for modifying the bone extracellular matrix to maintain the 
structural and functional properties of the fully differentiated bone cell  
In the bone, as observed with other cells and tissues, the relationship between growth 
and differentiation must be maintained and strictly regulated, both during embryonic 
development and throughout the life of the organism to support tissue remodeling. 
Understanding the factors regulating bone growth, the continue remodeling of bone 
throughout life and the regeneration of injured tissue are basic biological questions and 
concerns of today‘s clinician for the treatment of bone related disorders.  
 
- Transcription factors and bone related protein: osteoblastogenesis control  
In osteoblast (bone forming cells), the proliferation/differentiation relationship is 
controlled by a number of genes, some of which are specifically expressed in bone. 
Previous studies have demonstrated that, like osteoblasts, pulp cells express bone 
markers such as bone sialoprotein, ALP, Col I, and OCN (Kuo MY et al., 1992). 
During in vitro osteogenesis, the molecular and cellular mechanisms underlying the 
sequential differentiation of mesenchymal stem cells into osteogenic lineages have been 
the object of numerous studies. Several factors have been indentified which influence 
these processes (Banerjee C et al., 2001).  
OCN is the major bone-specific protein, produced by the mature osteoblast, which is 
expressed only post-proliferative during differentiation of normal diploid osteoblasts, 
when mineralization of extracellular matrix occurs. OCN is the most abundant non-
collagenous protein that constitutes 1-2% of the total bone protein or 20% of the non-
collagenous protein, and is the seventh most abundant protein of the human body. The 
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biological function of OCN has been correlated with bone turnover, and it has been used 
as a biochemical marker for the clinical evaluation of bone metabolism. It is a small 
protein, Vitamin K-dependent, that contains three residues of calcium-binding amino 
acid g-carboxyglutaminic acid (Gla), although the human protein contains only two Gla 
residues (Aronow MT et al., 1990). Gla residues are formed by a post-translational 
enzymatic carboxylation of glutamic acid, and allow specific conformational changes in  
presence of calcium and promote OCN binding to hydroxyapatite and subsequent 
accumulation in bone matrix. Transcription of the OCN gene is controlled by 
modulatory organized basal regulatory sequences and hormone responsive enhancer 
elements: these include the TATA box, which contain sequences for glucocorticoid 
receptor binding. 
 Bone sialoprotein is a highly sulfated, phosphorylated, and glycosylated protein that 
mediates cell attachment through a RGD motif to extracellular matrices (Ganss, B., et 
al., 1999).  Due to its highly negatively charged characteristics, bone sialoprotein can 
sequester calcium ions while conserving polyglutamate regions, which have 
hydroxyapatite- crystal nucleation potential (Hunter CK et al., 1993). In the absence of 
osteocalcin, bone sialoprotein could contribute to an overall metabolic shift toward new 
bone formation. 
A decade ago, Runx2 (Cbfa1) has been identified as the major transcription factor 
controlling osteoblast commitment and differentiation. It is a member of the Runt 
homology domain family of transcription factors, expressed in early mesenchymal cells 
at the onset of skeletal development, as well as in all osteoblast throughout their 
differentiation (Marie, PJ., 2008). Although Runx2 is the most abundant factor in 
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mature osteoblasts, Runx2 and Runx3 are also present in the osteoblast lineage. Runx2 
was found to control bone formation during both skeletal development and post-natal 
life (Karsenty G,  
2002). Molecular 
studies and genetic 
manipulation of Runx2 
in vivo indicated that 
the expression of 
Runx2 is both 
necessary and 
sufficient for 
mesenchymal cell 
differentiation towards 
the osteoblast lineage 
(Komori T et al., 2006) 
(Fig.12).  
 Its invalidation inhibits the differentiation of mesenchymal cells into osteoblasts and 
Runx2 haplo-insufficiency in humans‘ results in cleidocranial dysplasia, a disease 
characterized by defective bone formation. As a member of the Runx family of 
transcription factors, Runx2 operates in bone lineage cells by binding to the Runx 
consensus sequence (PuACCPuCA), first named the Osteoblast Specific Element 
(OSE2); its regulatory elements can be found in the promoter of all major osteoblast 
genes controlling their expression, including  type I collagen and sialoproteins, such as 
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osteocalcin and osteopontin. In addition to control osteoblast differentiation, Runx2 was 
found to negatively control osteoblast proliferation, by acting on the cell cycle (Pratap J 
et al., 2003): it can modulate the expression of kinases (such as p85 PI3K) that controls 
osteoblast differentiation and survival, and with several regulatory proteins within the 
nuclear architecture. Although its important role in osteoblast commitment, Runx2 is 
not essential for the maintenance of the expression of major bone matrix protein genes 
in mature osteoblasts. In fact, mice over-expressing Runx2 exhibit osteopenia, because 
of reduced number of mature osteoblast, indicating that Runx2 negatively controls 
osteoblasts terminal differentiation and maintains osteoblastic cell in an immature stage 
(Liu W et al., 2001). Molecular and genetic studies revealed that Osterix (Osx) is a zinc 
finger transcription factor indispensable for osteoblast differentiation and specifically 
expressed by osteoblasts: Osx deficient mice show absence of osteoblast and defective 
bone formation (Nakashima K et al., 2002). Osx transcription is positively governed by 
Runx2 and acts by directing pre-osteoblast to immature osteoblasts: Osx acts 
downstream of Runx2 (Runx2 is expressed in Osx-deficient mice). Although little is 
known about on the mechanisms of action of Osx, this protein was found to form a 
complex with the nuclear factor of activated T cells (NFAT), resulting in activation of 
COLIA1 promoter activity (Koga T et al., 2005). Accordingly, constitutive activation of 
NFAT activates the Wnt signaling pathway, bone formation and bone mass. The 
regulation of Osx is still poorly known: p53 was found to repress Osx transcription and 
thereby down-regulates osteoblastogenesis (Wang X et al., 2006). Osx modulate the 
expression of important osteoblast proteins such as OPN, OCN, bone sialoproteins and 
Col I. Osteopontin (OPN), also known as secreted phosphoprotein-1 (SPP1), urinary 
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stone phosphoprotein, uropontin, and early T-cell activator (ETA-1), is a highly 
conserved multifunctional phosphorylated glycoprotein expressed in many mineralized 
and soft tissues including bone, dentin, elastin, muscle, tumors, and in body fluids 
(milk, inner ear, and urine). It is also a major component of the calcium carbonate–
containing eggshell (Gerike A et al., 2005). In bone, OPN is produced by osteoblastic 
cells at various stages of differentiation, by differentiated osteoblasts and osteocytes, 
and also by osteoclasts. Studies on the temporal expression of OPN during the 
formation of bone in vitro and during the formation of intramembranous and 
endochondral bone in vivo, have revealed a pattern in which OPN is produced early in 
the osteogenic differentiation, in immature osteoblasts (McKee MD et al., 1995b), and 
then it is progressive down-regulated according to its role of mineralization inhibitor 
during bone development (Hunter GK et al., 1996).   
The similarity of the gene expression profiles and the expression of specific markers 
between DPSCs and precursors of osteoblasts has recently been reported (Fig.13) (Shi 
et al., 2001).   
  
48 
 
Foetal stem cells 
In recent years, foetal stem cells (FSCs) and stem cells isolated from cord blood or 
extraembryonic tissues have emerged as a potential ‗half way house‘ between ES cells 
and adult stem cells. FSCs can be found in foetal tissues such as blood, liver, bone 
marrow, pancreas, spleen and kidney, and stem cells are found in cord blood and extra-
embryonic tissues such as amniotic fluid, placenta and amnion (Marcus & Woodbury, 
2008). Their primitive properties, expansion potential and lack of tumorogenicity, make 
them an attractive option for regenerative medicine in cell therapy and tissue 
engineering settings. While extra-embryonic tissues could be used with few ethical 
reservations, the isolation of FSCs is subject to significant public unease (Abdulrazzak 
H et al., 2010 
  
49 
Foetal stem cells are advantageous for research for at least five reasons (Spitalieri P et 
al.,2009): 
 First, they are obtained routinely during gestation, using minimally invasive 
techniques, for prenatal diagnosis of a variety of developmental and genetic 
disorders. Several foetal stem cell types have been characterized at the molecular 
and cellular levels, including those cells harvested from amniotic fluid and 
umbilical cord blood, together with their differentiation capacity (De Coppi P et 
al., 2007; Fauza D, 2004; Guillot PV et al., 2007; O‘Donoghue  K et al., 2004). 
  Second, foetal stem cells have a higher potential for expansion than cells taken 
from adults. Investigators have discovered that mesenchymal cells from 
umbilical cord blood can be induced to form a variety of tissues when cultured in 
vitro, including bone, cartilage, myocardial muscle, and neural tissue (Bieback K 
et al., 2004). Foetal stem cells of mesenchymal origin are capable of self-
renewal, as well as to  differentiating into multiple tissue types (Tsai  M  et al., 
2004) 
 Third, the ability to isolate pluripotent autogenic progenitor cells during gestation 
may be advantageous for the timely treatment of congenital malformations or 
genetic diseases in newborns.  
 Fourth, foetal cells do not form teratomas when injected into adults and are either 
non immunogenic or less immunogenic, making them particularly suitable for 
transplantation. (Kakishita K et al.,2003). 
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 Fifth, their use is devoid of the ethical issues associated with embryonic stem 
cells (Weiss and Troyer, 2006). 
 Recent interest in stem cell biology and its therapeutic potential have led to the search 
for foetal stem cells in foetal organs obtained at termination of pregnancy, as well as for 
accessible sources of foetal stem cells that might be collected for autologous use in 
ongoing pregnancies. Until recently, foetal stem cells were thought to be multi-potent, 
but this picture is now changing as evidence is mounting, regarding the existence of 
pluripotent subpopulations in some foetal and extraembryonic tissues, such as placenta. 
(Cananzi M et al., 2009). 
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- Extraembryonic tissue: Placenta 
 
The placenta is a remarkable organ. Short lived by design, its brief existence enables the 
mammalian embryo/fetus to survive within the confines of the intrauterine environment. 
The diversity of functions performed by the placenta is impressive, ranging from 
anchoring the conceptus and preventing its rejection by the maternal immune system to 
enabling the transport of nutrients and wastes between the mother and the embryo/fetus. 
As with all organs, it performs these functions via multiple specialized cell types 
derived from lineage-committed precursors that either proliferate or differentiate. This 
process depends on a coordinated interaction among genetic, epigenetic, and 
physiological cues that are differentially interpreted as a function of gestational age. 
Each developmental event leading to the formation of a mature placenta is contingent 
upon the conditional transformation of prior structures (Maltepe E et al., 2010). 
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Developmental information, therefore, has its own history, i.e., an ―ontogeny of 
information,‖ that includes changes in the environment over time as an important 
variable (Oyama S, 2000).  Human placenta, besides playing a fundamental and 
essential role in foetal development, nutrition, and tolerance, may also represent a 
reserve of progenitor/stem cells. 
- Placental Compartments 
The foetal adnexa is composed of the placenta, foetal membranes, and umbilical cord. 
The term placenta is discoid in shape with a diameter of 15–20 cm and a thickness of 
2–3 cm. From the margins of the chorionic disc extend the foetal membranes, amnion 
and chorion, which enclose the fetus in the amniotic cavity, and the endometrial 
decidua. The chorionic plate (Fig. 13) is a multilayered structure that faces the amniotic 
cavity. It consists of two different structures: the amniotic membrane (composed of 
epithelium, compact layer, amniotic mesoderm, and spongy layer) and the chorion 
(composed of 
mesenchyme and a 
region of extravillous 
proliferating 
trophoblast cells 
interposed in varying 
amounts of Langhans 
fibrinoid, either 
covered or not by 
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syncytiotrophoblast). Villi originate from the chorionic plate and anchor the placenta 
through the trophoblast of the basal plate and maternal endometrium. From the maternal 
side, protrusions of the basal plate within the chorionic villi produce the placental septa, 
which divide the parenchyma into irregular cotyledons (Fig. 14). Some villi anchor the 
placenta to the basal plate, whereas others terminate freely in the intervillous space. 
Chorionic villi present different functions and structure. In the term placenta, the stem 
villi show an inner core of foetal vessels with a distinct muscular wall and connective 
tissue consisting of fibroblasts, myofibroblasts, and dispersed tissue macrophages 
(Hofbauer cells). Mature intermediate villi and term villi are composed of capillary 
vessels and thin mesenchyme. A basement membrane separates the stromal core from 
an uninterrupted multinucleated layer, called syncytiotrophoblast. Between the 
syncytiotrophoblast and its basement membrane there are single or aggregated 
Langhans cytotrophoblastic cells, commonly called cytotrophoblast cells (Parolini O et 
al., 2010)Foetal membranes continue from the edge of the placenta and enclose the 
amniotic fluid and the fetus. The amnion is a thin, a vascular membrane composed of an 
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epithelial layer and an outer layer of connective tissue, and is contiguous, over the 
umbilical cord, with the foetal skin. The amniotic epithelium (AE) is an uninterrupted, 
single layer of flat, cuboidal and columnar epithelial cells in contact with amniotic fluid. 
It is attached to a distinct basal lamina that is, in turn, connected to the amniotic 
mesoderm (AM) (Fig. 15). In the amniotic mesoderm closest to the epithelium, an 
acellular compact layer is distinguishable, composed of collagens I and III and 
fibronectin. Deeper in the AM, a network of dispersed fibroblast-like mesenchymal 
cells and rare macrophages is observed. Very recently, it has been reported that the 
mesenchymal layer of amnion indeed contains two subfractions, one having a 
mesenchymal phenotype, which is referred to throughout as amniotic mesenchymal 
stromal cells, and the second containing monocyte-like cells (Magatti M et al., 2007). A 
spongy layer of loosely arranged collagen fibers separates the amniotic and chorionic 
mesoderm. The chorionic membrane (chorion leave) consists of mesodermal and 
trophoblastic regions (Fig.15). Chorionic and amniotic mesoderm is similar in 
composition. A large and incomplete basal lamina separates the chorionic mesoderm 
from the extravillous trophoblast cells. The latters, similar to trophoblast cells present in 
the basal plate, are dispersed within the fibrinoid layer and express immune-
histochemical markers of proliferation. The Langhans fibrinoid layer usually increases 
during pregnancy and is composed of two different types: a matrix type on the inner 
side (more compact) and a fibrin type on the outer side (more reticulate). At the edge of 
the placenta and in the basal plate, the trophoblast interdigitates extensively with the 
deciduas (Cunninghan FG et al., 1997; Benirschke K et al., 2000). 
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- Embryological Development 
In humans, by days 6–7 after fertilization (during the implantation window), the 
blastocyst implants and placenta development begins. At this stage, the blastocyst is 
flattened and composed of an outer wall (trophoblast) that surrounds the blastocystic 
cavity. A small group of larger cells, the inner cell mass, is opposed to the inner surface 
of the trophoblastic vesicle. The embryo, umbilical cord, and amniotic epithelium are 
derived from the inner cell mass. As the blastocyst adheres to the endometrial, invading 
trophoblasts erode the deciduas, facilitating implantation of the blastocyst. By 8–9 days 
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after fertilization, trophoblastic cells at the implanting pole of the blastocyst proliferate 
robustly, forming a bilayered trophoblast. The outer of the two layers become the 
syncytiotrophoblast by fusion of neighboring trophoblast cells, whereas the inner cells 
(cytotrophoblast) remain temporally unfused. The proliferating cytotrophoblasts and 
the syncytiotrophoblasts give rise to a system of trabeculae intermingled with hematic 
lacunae. From these trabeculae are generated the primordial villi that are distributed 
over the entire periphery of the chorionic membrane. Villi in contact with the decidua 
basalis proliferate to form the leafy chorion or chorion frondosum, whereas villi in 
contact with the decidua capsularis degenerate into the chorion leave. At day 8–9 after 
fertilization, the inner cell mass differentiates into two layers: the epiblast and the 
hypoblast. From the epiblast, small cells that later constitute the amniotic epithelium 
appear between the trophoblast and the embryonic disc and enclose a space that will 
become the amniotic cavity. On the opposite side, between the hypoblast and 
cytotrophoblast, the exocoelomic membrane and its cavity modify to form the yolk sac. 
The extraembryonic mesoderm arranges into a connective tissue that surrounds the yolk 
sac and amniotic cavity, giving rise to amniotic and chorionic mesoderm (Fig.16). 
- Placenta-derived progenitor/ stem cells: 
The placenta is a fetomaternal organ involved in maintaining foetal tolerance and allows 
nutrient uptake and gas exchange with the mother, but also contains a high number of 
progenitor cells or stem cells (Parolini O et al., 2010). It has two sides: one foetal 
(amnion and chorion) and one maternal (deciduas). The availability, phenotypic 
plasticity and immunomodulatory properties of placenta-derived progenitor/ stem cells 
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are useful characteristics for cell therapy and tissue engineering (Abdulrazzak H et al., 
2010) .Cells can be isolated: 
1. during ongoing pregnancy using minimally invasive techniques such as 
chorionic villus sampling (CVS)  and placental tissues are readily available at 
delivery for allogeneic or autologous use; 
2. from the term placenta : placenta is a readily available tissue that is normally 
disposed off after delivery of the baby (Brooke G et al., 2009). 
 Cells that have been isolated from placenta include: 
a) hAECs: human amniotic epithelial cells (from the amniotic membrane),  
b) hAMSCs: human amnion mesenchymal stromal stem cells (both from amnion 
and chorion throughout gestation from first trimester to delivery) ,  
c) hCMSCs: human chorionic mesenchymal/stromal stem cells ( isolated during 
pregnancy CVS or from the term placenta at delivery), 
d) hCTC: human chorionic trophoblastic cells, 
e)  HSCs: human hematopoietic stem cells (Parolini O et al., 2008).  
 
- Chorion derived stem cells : Chorion Mesenchimal Stem Cells (CMSCs) 
Extensive phenotypical and functional characterization is available on hAMSC, wheras 
there are few reports of investigation on hCMSC (Soncini M et al., 2007). CMSCs have 
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been isolated during pregnancy (chorionic villus sampling, CVS, 9
th
-12
th
 week of 
gestation), or from placenta at delivery. The immunophenotype of term placental cells 
are similar to that of adult bone marrow MSCs, although renin and flt-1 have been 
shown to be expressed uniquely in the placenta MSC (Fukuchi Y et al., 2004). 
Mesenchymal placental cells are plastic adherent, share a similar immunophenotype and 
have lineage differentiation potential. They express stromal markers such as CD166, 
CD105, CD73, CD90 and others, while they are negative for the hematopoietic markers 
CD14, CD34 and CD45 (Sudo K et al., 2007). Additionally, they express pluripotency 
markers such as SSEA3, SSEA4, Oct-4, Nanog, Tra-1-60 and Tra-1-81 (Battula VL et 
al., 2007). 
Of relevance, MSCs from chorion, similarly to human amnion, successfully engraft in 
neonatal swine and rats (Bailo M et al., 2004), without a xenogenic response, indicating 
that these cells may have an immunoprivileged status consistent with their low level of 
HLA I and absence of HLA II expression (Kubo M et al., 2001). Of relevance for 
prenatal autologous and allogeneic therapy, chorion MSCs can be successfully isolated 
from chorionic villi during first-trimester gestation. The chorionic villi do not express 
typical MSC cell surface antigens and have the capacity to differentiate into lineages of 
the three germ layers, with a subset of cells expressing the pluripotency markers Oct-4, 
ALP, Nanog and Sox2 (Spitalieri P et al., 2009). 
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Bone tissue surgery 
 
Large bone defects that occur through trauma, loss of large bone areas after cancer 
surgery or bone loss through metabolic and degenerative diseases connected with 
weakening of the whole bone structure and the intrinsic regeneration mechanism, have a 
limited capacity for self-repair. Therefore, such bone defects could benefit from the 
development of novel treatments that take advantage of readily available and 
implantable bone grafts (Csaki C et al., 2009). Surgical methods such as autologous 
and/or allogenic osteochondral grafts have been established in surgical medicine and 
have been used for several decades to fill osteochondrotic defects. Patients with large 
defects, such as large bone defects after tumor resection, osteonecrosis, extensive 
trauma or broad focal osteoarthritis (OA) have especially benefited from these grafts 
(Marco P et al., 1993). However, the risk of donor site morbidity, infections from 
allografts or the sheer size of the implant are important limitations in reconstructive 
medicine and necessitate development of novel and innovative approaches to overcome 
these problems. These limitations have resulted in the development of new strategies to 
provide bone substitutes from in vitro production through tissue engineered bone 
constructs. Most of these evolve around bio-compatible and bio-degradable scaffold 
construction, seeding of scaffolds in vitro with adequate cells such as primary 
osteoblasts or mesenchymal stem cells (MSCs) or DPSCs and various combinations of 
growth factors. 
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The use of adult MSC-like populations provides an alternative and ethically acceptable 
source of multipotent cells instead of using embryonic stem cells, which have proved to 
be less practical and more controversial. 
Several studies have demonstrated that re-implanted MSC-like populations in vivo 
undergo site-specific differentiation and are capable of bone formation. This suggests 
that tissue specific cells may promote and enhance cells to differentiate towards their 
fully differentiated cell type by promoting dynamic and intensive cell–cell interactions. 
-3D Scaffolds 
Tissue engineering is a developing branch of science that merges the fields of cell 
biology, molecular biology, bioengineering, material science, and surgery to provide 
new functional tissue using living cells, biomatrices and signaling molecules. Using this 
technology, tissue loss or organ failure can be treated by implantation of an engineered 
biological substitute, that is either functional at the time of implantation or has the 
potential to integrate and form the expected functional tissue at a later stage.  
Three dimensional (3-D) cell cultures on a bio-degradable cell scaffold is the basis of 
tissue engineering, where the specific cells can grow and multiply into a structure 
similar to tissue or organs in the living body (George J et al., 2006). 
Bone formation requires a three-dimensional scaffold to drive cellular growth and 
differentiation (Donzelli E et al., 2007). An ongoing increasing numbers of biomaterials 
have been proposed as scaffold for tissue regeneration, whit the aim of reproducing the 
setting (or milieu) where the complex interaction between cells and their matrix. 
 
To achieve this goal, an ideal scaffold: 
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 should act as a biomimetic platform allowing cells to properly accommodate and 
rebuild the target tissue; 
 it should feature physical and chemical cues (like bioactive signals) that 
stimulate cell commitment, differentiation and regeneration of target tissue ; 
 It must be easy to shape it onto the bone defect; 
 It can also provides mechanical support against in vivo forces (Atala A ,2009); 
 It must have a reabsorbition time compatible with the time require for bone 
formation, but not so long to interferes with the bone substitution of the scaffold 
(Donzelli E et al., 2007). 
Generally, three classes of biomaterials have been used for tissue engineering: naturally 
derived, such as Collagen and Silk fibroin; extracellular matrices, like Matrigel
TM
 and 
synthetic polymers, such as poly-lactic acid (PLA) or P(d,l)LA. 
 
Matrigel
TM
 
Matrigel
TM
 basement membrane is 
composed by thin extracellular matrices 
underlying cells in vivo. It is a solubilized 
basement membrane preparation extracted 
from the Engelbreth-Holm-Swarm (EHS) 
mouse sarcoma, a tumor rich in 
extracellular matrix proteins. Its major 
component is laminin, followed by 
collagen IV, heparan sulfate proteoglycans, entactin/nidogen. 
 
Matrigel
TM
 also contains 
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TGF-beta, epidermal growth factor, insulin-like growth factor, fibroblast growth factor, 
tissue plasminogen activator,
 
and other growth factors that occur naturally in the EHS 
tumor. It is effective for the attachment and differentiation of both normal and 
transformed anchorage dependent epithelioid and other cell types:  neurons,
 
hepatocytes,
 
Sertoli cells, chick lens,
 
vascular endothelial cells and MSC.
  
         
Since its discovery in the 1980s, Matrigel has been used in numerous studies as an 
extracellular matrix for the in vitro and in vivo analysis of cell differentiation, 
invasiveness of tumor cells, and angiogenesis (Laschke MW et al., 2008). Because 
Matrigel contains a combination of 
different angiogenic growth 
factors, it ideally promotes the 
development of new blood vessels 
(Kleinman HK and Martin GR, 
2005). 
Matrigel matrix also supports in vivo propagation of human tumors in 
immunosupressed mice. 
(See BD datasheet PRODUCT: BD Matrigel™ Basement Membrane Matrix Phenol 
Red Free, 10 ml vial catalog number: 356237). 
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-Collagen Condress 
Condress is extracted from  bovine Achilles' 
tendon through a non-denaturing procedure in the 
absence of proteolytic enzymes. It has not been 
submitted to a chemical cross-linking process 
before lyophilization. Chemical identification of 
Condress as type-I acid-insoluble collagen has been carried out by evaluation of total 
nitrogen and hydroxyproline contents and by chromatographic examination. 
Electrophoretic analysis and morphological examination by electron microscopy 
confirm that the procedure employed to extract collagen does not alter the polypeptidic 
composition of the molecule and its structure. A gamma-ray dose between 0.5 and 1.5 
Mrad is quite adequate to sterilize the final product and certainly devoid of degradative 
effect. The finished product has a special (peculiar) absorbing capacity, immersion time, 
strain resistance, wrinkling temperature and enzymatic digestion time. It is a 
nonallergenic product suitable for clinical use. Condress  can be easily adapted to the 
application surface. When it has been applied in chronic leg ulcers, pressure sores, or 
reconstructive surgery, Condress seems to substantially improve wound repair: in these 
situations, Condress promotes the development and proliferation of granulation tissue .  
-Poly (d,l-lactide): P(d,l) LA  
Poly(lactic acid) or polylactide (PLA) is a biodegradable, thermoplastic, aliphatic 
polyester derived from renewable resources, such as corn starch (in the United States), 
tapioca products (roots, chips or starch mostly in Asia) or sugarcanes (in the rest of 
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world). Although PLA has been known for more than a century, it has only been of 
commercial interest in recent years, in light of its biodegradability.  
Polymerization of a racemic mixture of L- and D-lactides usually leads to the synthesis 
of poly-DL-lactide (PDLLA) which is amorphous. Use of stereospecific catalysts can 
lead to heterotactic PLA, which has been found to show crystallinity. The degree of 
crystallinity, and hence many important properties, is largely controlled by the ratio of 
D to L enantiomers used, and to a lesser extent on the type of catalyst used. 
 The addition of hydrophilic polymers into the PLA material, has been suggested as a 
method of increasing both the water uptake and degradation rate of polymers, thus 
enhancing the dissolution of drugs. Several methods have been used to achieve these 
polymers: the high temperature plasticisation of PLA with poly(ethylene glycol) (PEG), 
co-polymerisation of poly(L-lactide) (PLLA) and PEG and chemical modification 
through photo-grafting of the hydrophilic component to the PLA material. PDLLA are 
hydrophobic, slowing the rate of water ingress and taking up to 6 months to degrade 
slowing the release of any entrapped (Ginty PJ et al., 2008). 
-Silk fibroin 
Silks are naturally occurring protein polymers produced by a wide variety of insects and 
spiders that have been used clinically as sutures for centuries. When naturally extruded 
from insects or worms, silk is composed of a filament core protein, termed fibroin, and 
a glue-like coating consisting of sericin proteins. In recent years, silk fibroin has been 
increasingly studied for new biomedical applications due to the  
 biocompatibility, 
  slow degradability , 
  
65 
 remarkable mechanical properties of the material (Wanga Y et al., 2006) that 
resemble those of several structural tissues in the body, and has been 
successfully explored for the tissue engineering of bone, cartilage and ligaments. 
When appropriately purified, silk fibroin (SF) is non-toxic, non-immunogenic and has 
been demonstrated to support cell and tissue growth (Altman GH et al., 2003). 
The diverse functions of silks range from web construction and prey capture (spider 
webs), safety line (draglines) to reproduction (cocoons), and numerous studies have 
explored the potential of native and regenerated silk fibroin-based biomaterials in 
various forms, including films/membranes, micro/nano-fiber mats/nets, hydrogels, and 
porous sponges.  
Silks provide an excellent combination of lightweight (1.3 g/cm3), high strength (up to 
4.8 GPa as the strongest fiber known in nature), and remarkable toughness and elasticity 
(up to 35%). In summary, SF is a well-established biomaterial for tissue scaffolding 
mainly owing to its amenability to form tissue conductive microstructures (Fig.17). 
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Dental pulp extraction and digestion 
 
Cells were isolated from dental pulp as described in a previous study (Laino G et al., 
2006). Human dental pulp was extracted from third molar or permanent teeth of adult 
subjects (18 and 35 years of age) after informed consent of patients  undergoing routine 
tooth  extraction (only disease-free patients). 
Dental pulp was removed from the teeth with a dentinal excavator or a Gracey curette, 
and then immersed in a digestive solution (3 mg/mL type I collagenase plus 4 mg/mL 
dispase in-MEM) for 1 hour at 37°C. 
Once digested, the pulp tissue was chopped, dissociated, and then filtered onto 100m 
Falcon Cell strainers to obtain a cell suspension.  
 
Cell culture  
 
Cells were then plated and cultured in culture medium (-MEM with 20% FBS, 100 
M 2P-ascorbic acid, 2 mM L-glutamine, 100 U/mL penicillin, 100 g/mL 
streptomycin), in a humidified atmosphere of 95% air with 5% CO2 at 37°C. The 
medium was changed twice a week. Just before cells become confluent, they were 
subdivided into new flasks by trypsinization (0.05% trypsin/EDTA solution). 
Cells obtained from a single dental pulp were subcultured or plated at clonally density 
(1.6 cell/cm
2
) to obtain a single clone. After 6 days of culture eight cell populations 
were isolated from nodules originated by single cells. One of the expanded cell cultures 
from each sample/experiment was storage in vials of 1 million cells per vial: the vials 
were plunged into LN2 ( Liquid Nitrogen) at -196°C.  
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Term placental sample collection  
 
The term human placentae were collected, for this study, with an average patient 
gestation of 38 ± 1weeks (mean±SD). Delivery mode was elective Caesarean section. 
The study was performed with informed consent according to Italian law and ethical 
committee guidelines that approved the use of term placenta tissue for this work.  
Following collection, the umbilical cord was trimmed, close to the placental surface, 
and an X-shaped incision were cut into, but not through, the placental tissue (Fig.1). 
The amnion membrane was peeled from the underlying chorion layer of the placenta 
body and discarded. 2 cm cubes of chorionic placental tissue were then cut and  the 
samples were rinsed in physiological solution, to wash the blood in excesses.  
 
 
 
 
 
 
 
 
 
-Cell culture: placenta 
       The sample was washed 3 times in PBS solution, than enzymatically dissociated in a 
solution of Collagenase type IA (Sigma) 1%(w/v) in water diluting in MEM with 1% 
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of penicillin: streptomycin (pen:strep) solution  for 90 min  at 37°C. Before the 
incubation with collagenase type IA, the sample were mechanically disrupted with a 5-
ml syringe and a 16-G needle. After the incubation, the cell solution was passed three 
times through a 20-G needle, filtered through a 50 m cell strainer and centrifuged 5min 
at 300xg. 
        The supernatant was removed and the pellet was washed by adding 5ml of medium, 
and then resuspended in the culture medium and transferred in a flask.  The medium 
was change twice a week, and the cells were cultured for 10 days. 
 
Magnetic-activated cell sorting (MACS®) 
 
DPSC were obtained by magnetic cell sorting using MACS® separation Kit (Miltenyi 
biotech, Germany), according to the manufacturer instructions. Three successive sorting 
were performed by using specific antibodies: 
 Mouse anti-CD34 (Millipore Corporation), a marker of stromal and 
hematopoietic       pluripotent stem cells (Simmonson, PJ., 1991); 
 Rabbit anti-c-Kit (Santa Cruz Biotechnology), the tirosin-kinase receptor of stem 
cells factor (Barclay, AN., et al., 1988); 
 Mouse IgM anti- STRO-1 (Santa Cruz Biotechnology), an antigen present in a 
stromal cell population containing osteogenic precursor (Gronthos, S., et al.,  1994). 
   
These primary antibodies were detected by magnetically labeled secondary Abs (anti-
mouse IgG, anti-rabbit IgG and anti-mouse IgM, all from Miltenyi Biotech, Germany). 
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For each selection approximately 7x10
6 
cells were used. Firstly, pulp cell expanded in 
culture, was sorted by anti-CD34 Ab. CD34
+
 cells were expanded and then sorted by 
using anti-c-Kit Ab to obtain a CD34
+
/ c-Kit
+ 
population. In the same way the CD34
+
/ 
c-Kit
+ 
population was sorted by anti-STRO-1 Ab to obtain the CD34
+
/ c-Kit
+
/STRO-1
+
, 
that represents a selected subpopulation of DPSC called Stromal Bone Producing( SBP-
DPSC) as described by Laino et al., (2005).  Human term placental cells were sorted 
only for c-Kit: we obtained, as previously described, c-Kit
+
 placental cells. 
 
Flow Cytometry analysis  (FACS) 
The expression of CD34, c-Kit and STRO-1 antigens was analyzed by indirect staining, 
using mouse anti CD34 IgG, rabbit anti c-kit, and mouse anti STRO-1 IgM, followed by  
sheep anti-mouse FITC, goat anti rabbit-FITC and goat anti-mouse IgM- FITC (Jackson 
Immuno Research, USA). 
Non-specific fluorescence was assessed by using normal mouse IgG or IgM followed 
by secondary antibody as described above. Analysis were performed with a EPICS XL 
flow cytometer (Beckman Coulter, Brea, CA, USA). All experiments were performed in 
independent triplicates. 
 
 
Osteogenic differentiation in vitro:2D 
In order to obtain a differentiation into osteoblast on 2D surface, DPSCs were seeded at 
3000 cells/cm
2 
on culture dishes in the osteogenic medium (α-MEM, supplemented with 
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10% FBS, 100 μM 2P-ascorbic acid, 2 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin, 100nM dexamethasone, 10mM -glycerophosphate). The medium 
was changed twice a week. Control DPSCs were cultured in the same medium without 
dexamethasone, -glycerophosphate and ascorbic acid. For immunofluorescence 
experiments DPSCs were differentiated on Thermanox
®
 plastic cover-slips. Cell 
counting was performed in control and in dDPSC of three independent experiments by a 
Nikon TE2000 inverted Microscope using a 10x objective and  differential interference 
contrast (DIC). For each experimental point, the mean of cell number were calculated 
and cell density was expressed as cells/cm
2
. 
 
-Scaffolds 
 
Silk fibroin scaffolds were prepared and sterilized for cell cultures according to 
previous established protocols (Bondar B et al., 2008). Degummed silk fibers were 
soaked into 98–100% formic acid (Riedel-deHae¨n, Seelze, Germany), at room 
temperature, and the acid solution was evaporated under atmospheric conditions. The 
average fiber diameter of the scaffolds was between 100 and 200 nm and the thickness 
of the matrices was measured in the dry state and in the wet state as well. Nets were 
repeatedly washed with double distilled water in order to remove any residual acid and 
kept in wet conditions and sterilized by gamma rays. To prepare the fibroin nets for cell 
culture, the material was cut into disc-like shape with a height of 1.5 mm, diameter of 
5.2 mm and pore size of 250–420 m that allows cells to migrate into the nets.   
The numbers of scaffolds used were indicated above. 
 
  
72 
Osteogenic differentiation in vitro:3D 
 
Matrigel
TM
 (Becton, Dickinson) Collagen Sponge (Condress, ABIOGEN PHARMA 
s.p.a.), P(d,l)LA, and silk-fibroin were used as 3D scaffolds in this study. Cells were 
seeded in each scaffolds in an adequate volume of medium to obtain a starting density 
of 1000 cell for mm
3
. For every samples, cells were added to Matrigel
TM
 at 4°C when it 
appears as liquid. A total volume of 400 l of DPSCs-MatrigelTM was placed in a 12 
multiwell plate in order to form a 1 mm thick layer, which was polymerized at 37°C.  
DPSCs were injected in a 500 mm
3
 sample collagen sponge by a micropipette tip in 
different points to obtain a homogenous cell distribution. After 8 hours from cells 
seeding, 2 ml of osteogenic medium was added to each sample. The medium  was 
changes twice at week. 
For the differentiation studies on 3D scaffolds, the P(d,l)LA scaffolds (slightly 
hydrophobic) were soaked in ethanol for 30 min and then exchanged with phosphate-
buffered saline (PBS) for three times (30 min each). 
 The scaffolds were then washed twice with MEM medium containing 20% FBS (2 h 
for each rinse). 1000cells/mm
3
 were seeded on each scaffold and transferred 24 h later 
into 12-well tissue culture plates containing 3 mL of MEM medium per well 
supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin 50 mg/mL 
supplemented with the differentiating elements: 10 mM b-glycerophosphate,  100nM 
dexamethasone and 100 μM 2P-ascorbic acid,  for up to 4 weeks in an incubator at 37 
°C with 5% CO2.  Collagen Sponge and Fibroin were rinse, before seeding, with 
medium without the differentiating supplements. The rinse were performed to prepare 
  
73 
the scaffolds for the successive culture-conditions. The same amount of cells was 
seeded in each scaffold following the previously described. 
Western Blotting 
 
Whole cell lysates were obtained from undifferentiated and differentiating DPSCs at 
different times of culture. Cells lysates were obtained by addition of a Lysis Buffer (20 
mM Tris-Cl, pH 7.0, 1% NP-40, 150 mM NaCl, 10% Glycerol, 10 mM EDTA, 20 mM 
NaF, 5 mM Sodium Pyrophosphate, 1 mM Na3VO4, and freshly added Sigma-Aldrich 
Protease Inhibitor Cocktail) at 4°C for 10 min. After sonication, lysates were cleared by 
centrifugation for 15 min at 14,000g in a refrigerated centrifuge. The protein lysate were 
then added to SDS (Sodium Dodecyl Sulphate) sample buffer and 20% of 10mM 
Mercaptoethanol, and immediately boiled. 
50g of protein extract, quantified by a Bradford Protein Assay (Biorad; Bradford, 
1976) from each sample, underwent 10% or 15% SDS-polyacrylamide gel 
electrophoresis and then blotted onto a PVDF membrane. The protocols of the western 
blot were performed as described by Sambrook et al (Sambrook, J., 1989). The 
membrane was blocked with 3% dry milk and 2% bovine serum albumin (BSA) in 
phosphate-buffered saline–Tween 20 (0.1%) for 30min. Blots were incubated overnight 
with one of the primary  Abs (diluted 1:1000 in blocking buffer: TBS-T + 2% BSA and 
3% milk): anti-CD34, anti-c-Kit, anti-STRO-1, anti-Runx2, anti-OCN, anti-OPN and 
anti-Osx. After washing three times in blocking buffer, membranes were further 
incubated with peroxidase-labelled
 
anti-rabbit, anti-mouse or anti-goat secondary abs 
diluted 1:5000, for 30 min at room temperature. Following further washing in TBS-T, 
all membranes were
 
detected using ECL (Enhanced ChemioLuminescence, 
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Amersham). Anti-actin Ab was used as control of protein loading in timing 
experiments.  
To detect secreted OCN (sOCN) each sample was cultured with 2.5 ml of medium. 2 ml 
of medium were collected for each sample at the same time-point and then precipitated 
in 10% Trichloroacetic acid (TCA). Precipitated proteins were re-suspended in 0.1N 
NaOH in H2O and then in Sample Buffer. The whole protein amount obtained for each 
sample was loaded in the SDS-PAGE in order to have as a unique variable proteins 
secreted from dDPSCs. 
Densitometry was performed on WB from three independent experiments by NIS 
software (Nikon). An equal area (AOI) was selected inside each band and the mean of 
gray levels (in a 0-256 scale) was calculated. Data were then normalized to values of 
background and of control actin band.  
The same protocol was used to detect the expression of Oct4 in the whole cells lysates 
of placental cells after MACS® selection. Whole cell lysates were obtained from not 
selected, c-Kit+ and c-Kit- placental cells after 10 days of culture.  
 
 
 RT-PCR of c-Kit
+
 cultured placenta-cells. 
 
Total RNA isolation from c-Kit+ cells (placenta-sample), first-strand cDNA synthesis, 
and PCR were performed by using a TaqMan Gold RT-PCR Reagents kit (Applied 
BioSystems, Bedford, MA) with an oligo dT primer. First-strand cDNA (2 L) was 
diluted in a 20 L reaction mixture containing of GeneAmp Fast PCR Master Mix (2X) 
(Applied BioSystems)/500 nM of each human-specific primer sets (see Tab.1). The 
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reactions were incubated in a GeneAmp PCR system 9700 (Applied BioSystems) at 
94°C for 2 minutes for 1 cycle and then 94°C/(45seconds), 64°C/(45 seconds), 72°C/(60 
seconds) for 35 cycles, with a final 7-minute extension at 72°C. After amplification, 10 
L of each reaction was analyzed by 2% agarose gel electrophoresis, and visualized by 
ethidium bromide staining. 
Tab.1: Primer sequences for RT-PCR analysis 
 
 
 
 
 
 
Gene  Sequence  pb 
Oct4 sense 5‘-GTACTCCTCGGTCCCTTTCC-3‘ 167 
 a-sense 5‘-CAAAAACCCTGGCACAAACT-3‘  
hGADPH sense 5‘- AGCCGCATCTTCTTTTGCGTC-3’ 239 
 a-sense 5‘-TCATATTTGGCAGGTTTTTCT-3’  
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Osteogenic Differentiation on 3D surface for ectopic implant: 
subcutaneous implantation 
 
hDPSC-scaffold constructs were cultured in osteogenic medium for 1 week (medium 
changed twice) before implantation. For implantation, in the study male outbred rats 
with age ranging between 8 and 12 weeks (Charles River Laboratories) were used. The 
rat back was shaved, washed and disinfected with povidoneiodine. One mid-sagittal 
incision was made on the dorsa and two subcutaneous pockets were created using blunt 
dissection. One scaffold with a volume of 600 mm
3
 (15 mm  x 3.5 mm thickness) was 
implanted subcutaneously into each pocket. Each animal received consequently 2 
constructs. Three samples were implanted for each scaffold or scaffold/cell construct. 
The scaffolds were placed alternatively at different sites in each rat. Afterwards, the 
incisions were sutured with prolene 4-0 suture (Ethicon). Animals were 
immunocompromised using Cyclosporine A at a dosage of 15 mg/Kg b. wt., 
administered 4 h before transplantation and then daily for 2 weeks. During the last 2 
weeks the daily dosage was reduced gradually up to 6 mg/Kg b. wt. 
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4 weeks later rats were sacrificed and the cell-scaffold constructs were rapidly fixed in 
4% Paraformaldehyde in phosphate buffered saline (PBS). The animal procedures were 
performed according to the guidelines approved by the Committee of Use and Care of 
Laboratory Animals of the University of Modena e Reggio Emilia. 
    
Histology 
 
Samples of 2D or 3D cultures were fixed in 4% Paraformaldehyde in PBS at pH: 7.4 for 
15-60 min at room temperature. Samples were then washed twice with PBS and then 
processed for successive steps. Cells differentiated on Termanox coverslides were 
processed for immunofluorescence or histological staining. Matrigel samples were in 
toto processed. Collagen samples were firstly cryo-protected using a solution of 20% of 
sucrose in PBS for 1 day. The samples were placed on a support, embedded in Tissue-
Tek O.C.T (Sakura Finetek Europe) followed by a rapidly freezing in -75°C isopentane 
and then freezed in N2-liquid.  
Blocks of frozen collagen were cut into 10m thick cryo-sections, using a 
cryomicrotome (Zeiss, Germany), and mounted on Superfrost plus slides. Scaffold 
samples from in vivo ectopic implants, composed by Matrigel™, Collagen sponge, 
P(d,l)LA and Fibroin plus dDPSCs, were embedded in paraffin and cut in ten-
micrometer thick histological sections. 
Routine haematoxylin & eosin staining was performed on some samples to analyze 
morphological details. Fixed cells or ten-micrometer sections were stained with Alizarin 
Red S staining: the samples were incubated for 30 min at room temperature in a solution 
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containing 0.1% alizarin red and 1% ammonium hydroxide. Counterstaining with fast 
green was performed to visualize cell morphology.  
To demonstrate calcium deposition, sections were also stained with Von Koss Staining: 
the slides were incubated with 5% silver nitrate/H2O then exposed to UV lamp 20 mins. 
Rinsed in distilled water, slides were then treated with 2% sodium thiosulphate for  2 
mins, washed in running tap water and in distilled water, rapidly dehydrated, cleared 
and mounted.  Images of histological samples were obtained by a Zeiss Axiophot 
microscope equipped with a Nikon DS-5Mc CCD colour camera.  The percentage of 
mineralized area of every specimen was measured using ImageJ software (NIH, 
Bethesda, MD).  
Term placental tissues were embedded in paraffin blocks, using a common protocol. 
 
Immunofluorescence and Confocal microscopy 
 
Fixed monolayer cells were permeabilized with 0.1% Triton X-100 in PBS for 10 min. 
Permeabilized samples and histological sections were washed three times with 0.1M 
PBS. Samples from ectopic implants were incubated with 1 mM EDTA pH8 and 
exposed with microwaves (2 times at 750W), to unmask antigens.  
Then, all the slides, were blocked with 3% BSA in PBS for 30 min at room temperature. 
After washing, samples were incubated for 1 h at room temperature(RT) with the 
primary antibodies diluted 1:50 in PBS containing 3% BSA: rabbit anti-c-Kit, mouse 
anti-CD34, mouse IgM anti-STRO-1; rabbit anti-Runx2 (Abcam, UK); mouse anti-OPN 
(Santa Cruz Biotechnology); rabbit anti-Osx (GeneTex, USA); mouse anti-OCN 
(GeneTex, USA); mouse anti-Human Mitochondrial protein (Millipore Corporation), 
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mouse anti-Stella(Millipore Corporation),  mouse anti-Oct4(Chemicon USA), mouse 
anti actin( Millipore Corporation). 
The samples were washed in PBS containing 3% BSA, and incubated for 1 h at room 
temperature with the secondary Abs diluted 1:200 in PBS containing 3% BSA (donkey 
anti-rabbit-AMCA; sheep anti-mouse-FITC, and goat anti-mouseIgM-Cy5
TM
; donkey 
anti rabbit-Cy3
TM
). After washing in PBS, samples were stained with 1 g/ml DAPI in 
H2O for 1 min (not performed in samples treated with donkey anti-rabbit-AMCA Ab) 
and then mounted with anti-fading medium (0.21 M DABCO and 90% glycerol in 0.02 
M Tris, pH 8.0). Samples not incubated were considered negative controls with the 
primary antibody.  
The multi-labelling immunofluorescence experiments were carried out avoiding cross-
reactions between primary and secondary antibodies. 
Fluorescent samples were observed by a Nikon TE2000 microscope equipped with a 
CCD camera Hamamatsu ORCA 285. Images were captured and processed by NIS 
software (Nikon). Confocal imaging was performed on a Leica TCS SP2 AOBS 
confocal laser scanning microscope. The confocal serial sections were processed with 
the Leica LCS software to obtain three-dimensional projections. The image rendering 
was performed by Adobe Photoshop software. 
 
Immunohistochemistry (DAB) 
 
Paraffin term-placenta slides were deparaffined and washed two times in PBS; the 
endogenous peroxidase activity was blocked with freshly made 0.3% H2O2 in methanol, 
for 20 minutes. After washing with PBS, to unmask the antigen epitope, we performed 
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as antigen retrieval, the citrate buffer method. The slides were arranged in a staining 
container, and were incubated for 15 minutes at 95-100°C with 10mM citrate buffer, pH 
6.0. Rinsed the slides with PBS, the sections were then blocked with 3% BSA in PBS 
for 30 min at room temperature. Then samples were incubated for 1 h at RT with the 
primary antibodies diluted 1:50 in PBS containing 3% BSA: rabbit anti-c-Kit, mouse 
anti-Oct4, and mouse anti-Stella. The samples were washed in PBS containing 3% 
BSA, and incubated for 1 h at room temperature with the peroxidase labelled-secondary 
Abs diluted 1:50 in PBS + 3% BSA (anti-rabbit-HRP, anti-mouse-HRP). After washing 
in PBS, samples were stained with DAB substrate solution (freshly made just before 
use: 0.05%DAB - 0.015% H2O2 in PBS) to reveal the colour of antibody staining (<5 
min until the desired colour intensity). 
The slides were washed in PBS, counterstained with Haematoxylin for 1-2 minutes, and 
rinsed in running tap water for < 15min. The slides were dehydratated before to be 
mounted with anti-fading medium (0.21 M DABCO and 90% glycerol in 0.02 M Tris, 
pH 8.0). 
 
 
Electron microscopy  
 
Samples processed for morphology observations were fixed in 2.5% glutaraldehyde in 
Phosphate buffer (pH: 7.4) for 1 h and post-fixed in 1% OsO4 for 1 h. Ultrathin sections, 
obtained from Durcupan embedded samples, were stained with uranyl acetate–lead 
citrate and then observed with a Zeiss EM109 Transmission Electron Microscope. 
Immunogold experiments were performed as previously described
 
(Riccio M et al., 
2001) Briefly, samples were fixed in 1% glutaraldehyde in Phosphate buffer (pH: 7.4) 
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for 1 h, dehydrated in ethyl alcohol (50%, 70%, 90%, 95% and 100%), diaphanized in 
propylene oxide and embedded in Durcupan resin. Following a preincubation in 0.5 M 
Tris–HCl, pH 7.6, 1% 0.14M NaCl, 0.1 % BSA (TBS buffer I), the samples sections 
were incubated for 1 h at room temperature with the primary Ab (Human collagen type 
I) diluted 1:50   in TBS buffer I.  After being washed in TBS buffer I and then in TBS 
buffer II (0.2M Tris–HCl, pH 7.6, 1% 0.14M NaCl, 0.1 % BSA), human collagen was 
detected, in ultrathin sections, by a mouse anti-human type I collagen Ab, diluted 1:20 
in TBS buffer II. After 1h of incubation, the primary Ab was revealed by a 10 nm gold 
labelled anti-mouse secondary Ab. Incubation of the grids with gold-conjugated 
secondary antibodies only was used as control.  
 
 
Statistical analysis 
Quantitative or semi-quantitative data were expressed as mean ± standard deviation 
(SD). Differences between experimental points were evaluated by Student's t-test. In all 
analyses, p values < 0.05 were considered a significant statistical difference. 
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DPSC: isolation and characterization  
Is generally accepted that MSCs can be recognized as adherent cells, capable of 
extensive proliferation, with a fibroblastic profile and with the ability to differentiate 
into mesenchymal lineage (in ours experiments into osteoblastic lineage). The cells 
obtained from dental pulp by enzymatic digestion were cultured, as described in the 
Materials and Methods, for several days to isolate DPSCs. After two days of culture, 
cells were adherent, showed a spindle-like phenotype and often aggregated in groups.  
 
Cell sorting  
Flow cytometric analysis (Fig. 1) of each of eight populations isolated from nodules, 
after 6 days of culture, originated from 1 single cell clone, showed that the percentage 
of c-Kit
+
, CD34
+
 and STRO-1
+
 cells were 64%, 46% and 98% respectively (mean 
values).  
The majority of nodule constituting cells expressed c-Kit, CD34 and STRO-1, and 
could be considered the SBP-DPSCs subpopulation isolated by Laino et al.(2005). 
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To improve the percentage of cells expressing c-Kit, CD34 and STRO-1 markers, 
immunoselection protocol was subsequently used. The use of MACS® technology to 
further characterize DPSCs, was restrictive because of the rarity of these cells, obtained 
after processing (approximately 10
5
 cells per pulp sample). To verify if positive-sorted 
cells were c-Kit
+
, CD34
+
 and STRO-1
+
, flow citometry and triple immunofluorescence 
experiments were performed by using specific antibodies.  
Flow citometry demonstrated that MACS® sorting improves the percentage of CD34
+
 
(plus 20%) and c-Kit
+
 ( plus 34%) cells (Fig. 2). 
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Immunofluorescence analysis  
Immunofluorescence profile of the sorted cells was done, detecting specific antigens, to 
show that the most of the sorted cells were simultaneously positive to the three antigens 
used for the 
sorting (Fig. 3). 
Each positive cell 
showed a diffuse 
labeling on the 
plasma 
membrane, with 
the three signals 
appearing mostly as separate pixels and without overlap or co-localization: blue for c-
Kit, green for cD34 and red for STRO-1. Only a small number of spots showed the co-
presence of two signals probably due to clusterization of receptors (Fig. 3 the 
yellow/orange signal). 
Western blot analysis 
To confirm the Ab specificity, 
whole cell lysate of sorted 
cells were probed for c-Kit, 
CD34 and STRO-1. The 
immunological results 
described, more precisely, the 
identity of the selected cells, 
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and was confirmed by WB experiments (Fig. 4). 
 
 Osteogenic differentiation on 2D surface 
In order to obtain osteogenic differentiation, DPSCs were plated on a plastic 2D surface,  
at the density of 3000 cell/cm
2
 and then cultured in osteogenic medium for up to 40 
days. Osteogenic differentiation was evaluated by morphological, biochemical and 
immunocytochemical methods. DPSCs treated with culture medium alone represented 
control cells. The differentiating cultures and control cells were observed by phase 
contrast microscopy to evaluate the morphological changes and the proliferation rate 
(Fig. 5). 
In monolayer culture, seeded cells showed a fibroblast-like morphology (fig.5A).  
The cells proliferated and reached the confluence at day 8 in both differentiating and   
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control cultures (Fig. 5 E, B).  
At this time, dDPSCs showed a lower cell density and presented a cytoplasm more 
extended (Fig. 5E). After day 8 control cells proliferated actively and formed 
overlapped layers that become evident at day 24 and 40 (Fig. 5 C, D). On the contrary, 
differentiated cells were characterized by a lower proliferation activity and started to 
form nodular aggregates at day 24 (Fig. 5 F and inset). At day 40, in differentiated 
cultures, mineral deposits appeared in the extracellular space and in nodular aggregates 
(Fig .5 G, H).  
Cell counting indicated that differentiating cells presented the same high levels of 
proliferation, similar to that of control DPSCs, until day 8. Then undifferentiated 
DPSCs continued to grow exponentially and at day 40 reached a density of over 
150.000 cells/cm
2
. On the contrary, differentiating DPSCs showed a lower proliferation 
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activity until day 24. After this time the number of dDPSCs were slightly decreased 
(Fig. 6). 
 
Western blot analysis 
To verify the commitment and differentiation of DPSCs into osteoblast-like cells, the 
presence of specific markers, such as Runx2, Osx, OPN and OCN, was analyzed by WB 
in whole lysates of dDPSCs, at different differentiation-time points (Fig 7 A). 
A densitometric analysis was carried out on the WB bands to obtain a semi-quantitative 
analysis of the protein amount (Fig. 7 B). 
Runx2 was detectable in all the experimental time points, but presented significant 
expression peaks. The two major peaks occurred at days 8-16, indicating the starting of 
DPSCs differentiation, and the third peak was evident at day 32. Runx2 amount 
92 
 
decreased at days 24 and 40 suggesting a down-regulation of this protein. Osx was 
weakly present at day 16, then it increased, showing two expression peaks at day 24-32, 
while at days 40 the protein level slightly decreased. The expression of OPN was 
evident from day 8 to the end of the experiment, reaching an expression peak at day 16  
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and decreasing progressively until day 40. OCN was detectable during DPSC 
osteogenic differentiation, both in cell lysates and in culture medium, as secreted 
protein (sOCN). This protein was significantly expressed in whole lysates from day 16, 
increased at day 24, then decreased at day 32 and  reached the highest level at day 40 
(Fig. 7C). 
 
 
 
Immunofluorescence analysis  
Western blot results were confirmed by immunofluorescence analysis. Double 
immunofluorescence labeling was carried out to analyze simultaneously the localization 
of OPN and Runx2 in dDPSC (Fig. 8 A, F). The distribution of OCN and Osx (Fig. 8 G, 
L) was observed in the same manner. During DPSCs osteogenic differentiation, OPN 
was localized in the cytoplasm, above all in the perinuclear region that normally 
contains the RER (Fig. 8 A, C, E; green signal). Runx2 was localized in the cell 
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nucleus, as demonstrated by the overlapping with DAPI signal, and the nucleoplasmatic 
distribution typical of transcription factors could be observed (Fig. 8 B, D, F and insets; 
DAPI, blue signal; Runx2, red signal). At day 8 it was present approximately in all 
nuclei, while at day 24, when a strong decrease was observed by WB, it was mainly 
expressed in nodular aggregates, and nuclei of manolayered cells showed a lower 
labeling. At day 40 Runx2 appeared heterogeneously expressed al low levels only by 
some cells (Fig. 8 A, F; red signal).  Immunofluorescence analysis using anti-OCN and 
anti-Osx also confirmed WB data. OCN showed typical cytoplasmatic localization with 
a pattern compatible with the distribution of RER (Fig. 8 G, I, K, green signal) and, as 
well as Runx2, showed a nucleoplasmatic localization (Fig. 8 H, J, L). It was interesting 
to note that the signals from the two proteins increased significantly at days 24 and 40 
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(Fig. 8 I, L) and that nodular aggregates were more labeled then cells of surrounding 
monolayer (Fig. 8 I,J ). At day 40 we observed a significant change of cell morphology 
with evident cellular processes typical of differentiating osteoblasts (Fig. 8 E, K). 
 
Histochemical analysis  
In order to verify if dDPSCs were able to produce calcified matrix, cells were stained 
with Alizarin red and counterstained with fast green. The presence of calcium deposits 
became evident after 40 days of culture (Fig. 8  M, N), when nodular aggregates 
appeared stained in red/orange. It was interesting to note that cells entrapped in calcium 
deposits showed an osteocyte-like morphology (Fig. 8 M and inset). 
96 
 
 
 Osteogenic differentiation on 3D scaffolds 
To evaluate DPSCs differentiation in 3D scaffolds, cells were cultured and 
differentiated in two commercial devices: i) BD Matrigel™, a solubilized extracellular 
matrix preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma; ii) 
Collagen Sponge, a biomaterial made of insoluble equine type I collagen, already used 
in clinical practice as scaffold to support bone regeneration. Cells were seeded in both 
scaffolds at the density of 1000 cell/mm
3
 and treated for osteogenic differentiation for 
up to 40 days. Cell growth and osteogenic differentiation were evaluated at day 40 by 
histological, immunocyochemical and ultra-structural methods.  
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Matrigel™ 
DPSCs seeded into Matrigel appeared distributed in all the volume of the sample. They 
grew actively during the first week and formed numerous cellular aggregates distributed 
homogenously throughout the culture plate (Fig. 9 A). Each cellular aggregate, 
composed of cells with spindly-type morphology, showed a core with a higher cell 
density than the marginal area. The peripheral cells were in contact with cells of the 
near aggregates and probably interacted, forming a cellular network (Fig. 9 B). 
98 
 
Confocal analysis of immunofluorescence experiments with anti-OPN and anti-OCN 
Abs showed that cells of nodular aggregates expressed the two proteins after 40 days of 
culture (Fig. 9 C, D) indicating that DPSCs were differentiating in osteogenic lineage. 
The Alizarin red staining of 40-day samples showed that nodular aggregates contain 
calcium deposits localized in the matrix close to the cells (Fig. 9 G, H).   
TEM analysis of dDPSCs, cultured in Matrigel™, demonstrated that peripheral cells of 
nodular aggregates were connected by junctions probably classifiable as gap-type (Fig. 
9 G, H). 
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Collagen Sponge 
H&E staining showed that DPSCs colonized collagen scaffold, penetrating into the 
sponge and proliferating three-dimensionally. Cells were not homogenously distributed 
in the sponge thickness, showing a higher cell density in the superficial layer, that 
decreased progressively towards the centre of the sponge (Fig. 9 I). Superficial cells had 
a flattened morphology and formed a thin compact layer of 4-5 cells. Cell morphology 
changed from the surface to the inner center of the sponge and became progressively 
spindle-type with cellular process typical of differentiating osteoblasts (Fig. 9 J). In the  
 
sponge aggregates of collagen fibers were visible, surrounded by cells resembling 
trabecular-like structures (Fig. 9 I, J arrows). 
Immunocytochemical evaluation of osteogenic differentiation showed that dDPSCs 
growing in collagen sponge expressed both OPN and OCN osteogenic markers. OPN 
was strongly expressed by DPSCs localized in superficial layers and was less present in 
the inner ones (Fig. 9 K). Cells positive to OPN Ab were strictly adherent to collagen 
fibers associated in trabecular-like structures, as also observed by H&E staining 
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(arrows). DPSCs, localized in inner layers or near the trabecular-like structure, 
presented an osteoblast-like morphology and expressed higher levels of OCN, with 
respect to superficial cells (Fig. 9 L). Alizarin red staining showed that calcium deposits 
were present in the whole sponge thickness and much more in trabecular-like structures 
(Fig. 9 M, N). 
 
TEM analysis of dDPSC, cultured in the collagen sponge, demonstrated that cells were 
inter-connected by gap-junctions as described for Matrigel (data not shown). The 
assembling of neo-synthesized tropo-collagen molecules in collagen sub-microscopic 
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fibrils, was well visible both in sagittal and in transversal sections (Fig.10 A, B). To 
verify if sub-microscopic fibrils were effectively secreted by dDPSC, immunogold 
experiments with anti Human Collagen type I Ab were carried out. This Ab recognize 
collagen I of human origin but it does not react with the equine type I collagen of the 
sponge (Fig.10 C, D). Immunogold experiments demonstrated that sub-microscopic 
fibrils were clearly labeled by anti-Human collagen I Ab (Fig.10 D arrows). On the 
opposite, equine collagen fibers of the sponge were not labeled by anti Human collagen 
I Ab (Fig.10 D, arrowhead). 
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Osteogenic Differentiation on 3D surface for ectopic implant 
In order to study the bone forming ability of hDPSCs on collagen, fibroin and P(d,l)LA 
scaffolds, ectopic implants were performed following the protocol previously described. 
Each scaffold (without cells, as control, and with dDPSCs), was tested in three different 
animals (Fig. 11). Stem cells-scaffolds were induced in osteogenic medium for 7 days 
and were subcutaneously implanted into rats treated with immune-suppressing agent 
(Fig. 12). 
 
Four weeks after subcutaneous implant, control-collagen was completely and rapidly 
reabsorbed (Fig. 13 A), while dDPSCs-collagen showed a strong reabsorbition, with a 
inflammatory response near the implant (Fig. 13 B, A H&E). 
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A 
B H&E A H&E 
C B 
Fig.13 A: Control-Collagen scaffold, was entirely reabsorbed after 4 weeks.B: dDPSC-
Collagen scaffold, had a strong, but not complete, reabsorbition. A H&E: dDPSC-
Collagen scaffold showed an inflammatory response near the implant. Foreign body 
giant cells (arrow) were probably generated in response to the presence of a large 
foreign body (dDPSC-Collagen scaffold). C: Alizarin red staining showed a low 
mineralization in dDPSC-Collagen scaffold . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Alizarin red staining scaffold showed a low mineralization (Fig. 13 C) of the 
subcutaneous implant. The inflammatory response against the dDPSC-collagen 
construct was also characterized by the presence of foreign-body giant cells, as shown 
in Fig. 13 B ( H&E). 
After 40days, the implant of fibroin scaffold alone (control sample), did not present 
mineralized matrix (Fig. 14 B-D), while a significant presence of cells was found near 
the scaffold (Fig.14 A –C). 
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A significant ectopic calcium deposition was found in dDPSC/fibroin construct, as 
showed by Alizarin staining (Fig. 15 B, D) and by Von Kossa staining (Fig. 15 E). 
Ematossilin/eosin (H&E) staining showed mineral deposition inside the scaffold area 
(Fig. 15 A, C), indicating that fibroin was a suitable scaffold for bone regeneration by 
stem cells. 
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On the other hand, mineralization in P(d,l)LA scaffolds did not occur (Fig. 16), which 
was confirmed by Alizarin staining for the determination of calcium contents in the 
scaffolds, both in the control-scaffold as in the hDPSC/P(d,l)LA scaffold after 40 days 
of implant ( Fig. 16 B, D, E).  
Therefore, the in vivo data showed that fibroin scaffolds provided dDPSCs with a more 
favourable microenvironment for their osteogenic differentiation and bone formation 
than P(d,l)LA scaffolds did.  
To check if cells inside the scaffold were still from human origin and not from the host, 
immunofluorescence experiments with anti Human mitochondria Ab were carried out. 
This Ab only recognizes mitochondrial protein from human origin. Data demonstrated 
that most of osteoblast-like cells were clearly labelled by anti Human mitochondria Ab 
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(Fig. 17 C, D), indicating that most of the stem cells remain inside fibroin construct 
subcutaneously implanted up to the end of the experiment. 
Cells not positive for the Human mitochondria Ab were host cells that probably 
participated to the osteogenic-process, creating a network between dDPSCS/scaffold 
and the regeneration of the bone defect.  
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Fig.17 Immunofluorescence analysis of Fibroin scaffold + dDPSC after 40 days.A-B 
Images of fluorescence signals from anti-h Mit protein (green) in fibroin scaffold 
alone. The signal of fibroin fibres was auto-fluorescence: in fact the fluorescence 
emission was both in the two colours (arrows).C-D: Images of fluorescence signals 
from hMit protein ( green) and Dapi (red) in fibroin scaffold+ dDPSCs.   
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Placenta 
Placenta: c-Kit
+ 
cells isolation 
The cells, obtained from term placenta by enzymatic digestion, were cultured for about 
10 days in culture medium, as described in M&M, to reach an appropriate amount of 
cells for the next steps. Cells expressing c-Kit were selected by MACS™ technology, to 
isolate c-Kit
+
 cells from the whole population. 
       To verify if sorted cells were c-Kit
+
, FACS analysis and immunofluorescence 
experiments were performed on selected cells (Fig. 18).  
       Sorted cells were observed by phase contrast microscopy to evaluate their morphology: 
seeded cells showed a fibroblast-like morphology, as previously described for DPSC. 
Immunofluorescence analysis showed that most of the sorted cells were c-Kit
+ 
(Fig.18 B 
red signal, DAPI: blue signal). Each positive cell showed diffuse labeling on the plasma 
membrane. FACS analysis demonstrated that almost 96.3% of the cells analyzed were 
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positive for c-Kit (Fig. 18 C blue line), with respect to the isotype-control (Fig. 18 C red 
line).  
 
 
Western Blot and PCR 
To verify the expression of the pluripotent marker Oct4 in cultured  placenta-cells after 
MACS® selection, PCR and WB analysis were performed. The selected population, c-
Kit
+
 placenta-cells expressed Oct4 specific transcripts as determined by PCR analysis 
(Fig. 19 A). WB experiments (Fig.19 B) were carried out in whole cell lysates of 
placenta-cells not selected (no MACS® selection), c-Kit
+ 
(positive selection) and c-Kit
- 
(negative cells fraction after c-Kit selection). Oct4 was detectable in c-Kit
+
 and in  not-
selected lysates of placenta-cells, and there was no band in c-Kit
-
 cell-lysates. Western 
blot experiments confirmed the expression of Oct4 protein in placenta-cells, showing a 
higher presence in c-Kit
+
 samples than in the not-selected cells.  
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Immunohistochemistry analysis on paraffin sections 
In serial sections of a placental sample, we first immune-localized the presence of c-Kit 
by an immunoperoxidase reaction: the antibodies were visualized via a peroxidase-
catalyzed reaction, in which Peroxide/DAB were the substrate and horseradish 
peroxidase (HRP). C-Kit staining was cytoplasmatic with an high intensity and a 
specific localization in the endoplasmic reticulum (ER). C-kit positive cells were 
localized around the vessels, probably in the “avventizia” (Fig. 20 A, B), but no  
 
immunoreactivity was detected into the mesenchymal cells forming the undifferentiated 
connective tissue in which these fetal blood vessels course through.  
A better resolution was given by Fig. 20 C: the strong cytoplasmatic staining, that 
confirms the protein localization, was detected in fibroblast-like cells around vessels, in 
the perivascular region. 
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Immunohistochemical results were confirmed by immunofluorescence analysis (Fig. 21 
A). Triple immunofluorescence labeling was carried out to analyze the  
 
 
 
 
localization of c-Kit (green signal) and -actin (red signal) in the placental slides. C-
Kit
+ 
cells showed a diffuse labeling on plasma membrane and cells were localized 
mostly around the vessels (Fig. 21 B).  
In Figures 22 A and B, the cytoplasmatic localization of c-Kit was also detected with 
immunohistochemical staining in big cells, characterized by a stained cytoplasm, a 
round morphology and a specific “peri-chorionic”  localization, between  the wall of  an 
anchoring villus (cut in longitudinal section) and the fibrinoid deposits .  
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To identify the distribution of cells positive for stem cell markers, as nuclear markers 
Oct4 and Stella, further immonohistochemistry analysis were performed (Fig. 23). 
Oct4 showed a typical nucleoplasmic localization in big cells surrounded by fibrinoid 
matrix: the cytoplasm of these cells was not labeled and was more extended than the 
cytoplasm of the neighboring cells (Fig. 23 A, B). The immunoperoxidase detection of 
Oct4 showed positive nuclei also in syncitiotrophoblast cells, in the floating villi (Fig. 
23 C-E). The cytoplasm of Oct4
+
 cells in the syncitiotrophoblast was brighter than the 
cytoplasm of the other cells (Fig. 23 D): this is a characteristic of undifferentiated cells, 
due to their quiescent state. 
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Within fetal villi, Stella positive cells were immerged in an undifferentiated connective 
tissue, with fetal blood vessels coursing through this region and fibrinoid deposits 
around the cells. Stella, a marker of 
pluripotent cells, was immunodetected 
in the nucleus of these cells located 
close to the syncitiotrophoblast layer 
(Fig. 24). 
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DISCUSSION: DPSC 
In this thesis, we analyzed the osteogenic differentiation features of DPSCs cultured on 
2D surface and on 3D scaffolds in vitro, and the ectopic implants of the 3D scaffolds, in 
vivo. DPSCs population, isolated from dental pulp of adults’ teeth that presents the c-
Kit, CD34 and STRO-1 antigens, coincides with the DPSC sub-population (SBP-
DPSCs) described by Laino et al., (2005). According to methods previously described, 
osteogenic differentiation of DPSCs was obtained by treatment with dexamethasone, to 
stimulate cell differentiation, ascorbic acid, to stimulate the extracellular matrix 
synthesis and -glycerolphosphate to promote ECM mineralization (Zhang W et al., 
2006; Karner E et al.,2008). DPSCs responded to this osteogenic condition with a 
strong decrease of proliferation after day 8 of culture, when the confluence was reached. 
Afterword  this, cells proliferate actively, forming overlapped layers, while dDPSCs 
grew as a monolayer showing typical mineral deposits and nodules as described by 
other authors (Laino G et al., 2005). After 24 days, the density of dDPSCs showed a 
slightly reduction, probably due to the increase of cell death that normally occurs during 
late cell differentiation. 
To verify if morphological observation really indicates an osteogenic differentiation, we 
investigated the expression of bone related proteins in dDPSCs. Recently Yu and co-
workers demonstrated that STRO-1
+
 DPSCs, after 9
th
 passage, can only differentiate in 
osteogenic lineage, expressing specific markers (Yu J et al., 2010). Different 
transcription factors and proteins typical of bone ECM were expressed during osteoblast 
differentiation. Only a small number of these can be used as stringent markers because 
they are clearly expressed in bone tissue or show typical expression peaks during 
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osteoblast differentiation. The DPSCs osteogenic differentiation observed in our 
experiments can be distinguished in two phases on the basis of expression of specific 
markers as RUNX2, Osx, OPN and OCN. The first phase, from day 0 to day 16, was 
characterized by a strong expression of Runx2 coupled with a greater presence of OPN. 
Runx2, actually expressed in undifferentiated cells, showed a considerable increase 
between 8 and 16 days, that coincided with the proliferation decrease and presumably 
with the starting of a late differentiation phases. OPN showed its maximum expression 
level at day 16 in coincidence with Runx2 peak and then decreased progressively to the 
end of culture. These observations indicated that this phase represents an early stage of 
osteogenic differentiation according to data that describe high levels of Runx2 and OPN 
in osteoblast proliferation (Pratap J et al., 2003). In the second phase, from day 16 to 
day 40, dDPSCs showed a low proliferation level and expressed a higher amount of Osx 
maintained until day 32. The increase of Osx occurring after Runx2 peak is consistent 
with data describing Osx positively governed by Runx2 during osteoblast differentiation 
(Marie PJ,  2008 ; Komori  T , 2006). In this phase, the regular increase of intracellular 
OCN levels and the strong presence of sOCN in culture medium indicated that dDPSC 
underwent a late differentiation phase characterized by an ECM maturation process. 
Previous data indicated that OCN is the most specific marker of late osteoblast 
differentiation because it is synthesized only by mature osteoblasts at the end of matrix 
maturation process (Sila-Asna M et al., 2007; Valenti  MT et al., 2008). The OPN 
decrease observed in this phase was supported by observation demonstrating the 
presence of OPN during osteoblast differentiation and its progressive down regulation 
according to its role of mineralization inhibitor (Karner E et al., 2008; Hunter GK et al., 
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1996). In our model, after the induction started with the first Runx2 peak, others 
osteogenic inductions could be promoted by following Runx2 peaks in order to 
maintain an immature sub-population of dDPSCs that underwent further terminal 
differentiation events. On the other hand, immunofluorescence data indicated that the 
decrease of Runx2, observed by WB at day 24, occured in the majority of dDPSCs 
while its expression was maintained in cells of nodular aggregates. On the contrary, Osx 
and OCN at day 24 were expressed both in nodular aggregates and in monolayer cells. 
Successively their presence characterized almost the entire cell population: this data 
suggested that nodular aggregates were contemporaneously composed of a sub-
population of immature dDPSC and by a dDPSC population that progressively 
underwent to terminal differentiation. The change in cell morphology at day 40, 
characterized by thin and long cellular processes, indicated that dDPSCs were in a very 
late differentiation phase. Furthermore, Alizarin red staining demonstrated that calcified 
ECM was produced and dDPSCs with an osteocyte-like morphology were entrapped by 
this.  
An optimal bone formation requires that osteoblasts grow and differentiate in this three-
dimensional (3D) environment, allowing the formation of an intercellular network. 
Previous studies indicated that osteogenic differentiation is improved by culture in 3D 
scaffolds that mime the physiological condition (Boukhechba  F. et al., 2009; Ferrera D. 
et al., 2002). Biomaterials play central roles as designable biophysical and biochemical 
milieus that direct cellular behaviour and function in regenerative medicine and tissue 
engineering (Langer and Vacanti, 1993; Lutolf  and Hubbel, 2005). Calcified tissue can 
be produced in vitro using bone marrow MSC cultured on collagen sponge or similar 
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bio-scaffolds, already utilized in surgery to support and improve bone regeneration 
(Gigante A  et al., 2008; Zavan B et al., 2007;Donzelli  E et al., 2007; Jager M et al., 
2005). In this study we compared Matrigel ™ and collagen sponge with new 
bioscaffolds, fibroin and P(d,l)LA, seeded with dDPSCs. Our data, obtained by 
culturing DPSCs on Matrigel™ and collagen sponge, indicated that both scaffolds 
optimize DPSCs growth and differentiation. The gelatinous structure of Matrigel™ 
mimes the amorphous extracellular matrix components (proteoglycans and GAG) 
allowing three-dimensional nodules formation. TEM analysis demonstrated that 
peripheral cells of these nodules were interconnected by gap junctions analogously to 
osteocyte network observed in bone tissue (Civitelli M,  2008; Palumbo C et al., 2004). 
A better result was obtained with collagen sponge because DPSCs colonized this 
scaffold with a distribution that mimed the bone histology: cells of superficial layers 
were less differentiated, as demonstrates by the clear expression of OPN that decreases 
in the inner layer. Moreover these cells present a very flat morphology and form a thin 
superficial layer that can be compared with the bone periosteum. Cells with osteoblast-
like morphology that express high levels of OCN (late differentiation marker) and 
actively neo-synthesized human collagen, were present in the inner layers, unlike 
superficial cells. In this region structures containing dense collagen fibres and calcified 
matrix that resemble bone trabeculae were observed (Riccio M et al., 2010).  
An ex vivo engagement in a specific pathway prior to transplantation may be needed to 
induce the differentiation into a desired cell lineage before cell transplantation therapy. 
As specifically described with bone marrow-derived stem cells (Dezawa M et al., 
2005), a good approach may be to initiate differentiation in vitro for a lineage-specific 
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pathway, allowing these cells to complete their development and acquisition of specific 
function in vivo. In our experiments, we cultured DPSCs/scaffold constructs in 
differentiating medium, for 7 days, before subcutaneous implant in rat. We 
demonstrated that mineralization of dDPSCs was more present on the fibroin scaffolds 
compared to collagen and P(d,l)LA scaffolds. The Alizarin Red staining results on 
sections of DPSCs/scaffold, after 1-month implant in vivo, provided more convincing 
evidence that fibroin scaffolds were more favourable for the osteogenic differentiation 
of dDPSC. The present study confirmed that the biomimetic microenvironment, 
provided by the fibroin scaffolds, is an important element besides the morphogenetic 
factors for the differentiation of the stem cells (Sun H et al., 2010). 
On the other hand, collagen and Matrigel scaffold, as ectopic implant, were completely 
absorbed, therefore this experimental approach did not give information about the 
employ of these scaffolds for engineering osseous grafts. P(d,l)LA is not a good support 
for osteogenic differentiation, as shown in the results; in fact there was no calcium 
deposition in the ectopic implant, probably due to its biophysical characteristics.  
-Conclusions 
In our studies, we demonstrated that DPSCs are able to differentiate in osteogenic 
lineage in both 2D and 3D surfaces, creating osteoblast-like cells that express specific 
osteogenic markers and produce mineralized ECM. The combination with 3D 
bioscaffolds was performed to produce a dDPSC-bioscaffold device that can be easily 
inserted by surgical intervention in order to repair bone tissue deficiency.  
This tissue engineering approach could be a promising tool to restore bone defects that 
currently are treated surgically through the application of artificial permanent implants. 
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In particular, the in vitro bone production from stem cells may represent a radical 
breakthrough in the treatment of congenital or acquired pathologies and secondary 
traumas characterized by critical bone mass defects, which even today resist any 
medical or surgical solution. In addition, DPSCs can also be used to colonize prosthesis 
and orthodontic implants in order to optimize the osteo-integration and the efficiency of 
the implant itself. To produce a large pool of cells and derived- progeny, it may be 
preferable to culture and expand autologous mesenchymal stem cells prior to 
implantation in an effort to personalize cell-based therapy and differentiate toward the 
necessary lineage (Nelson TJ et al., 2009). 
In addition, it is important to note that adult human mesenchymal stem cells, as DPSC, 
are characteristically devoid of human leukocyte antigen (HLA) class II antigens 
(MHC-II) on the cell surface, and do not express the co-stimulatory molecules CD80, 
CD86 or CD40 (Nelson TJ et al., 2009). The expressed major histocompatibility 
complex (MHC) class I antigens may activate T cells, but with the absence of co-
stimulatory molecules, a secondary signal would not engage, leaving T cells anergic. 
Moreover, DPSC exhibit immunosuppressive properties, modulating T-cell functions 
including cell activation, and display immunomodulatory features impairing maturation 
and function of dendritic cells and inhibiting human B-cell proliferation, differentiation, 
and chemotaxis. 
Understanding the interactions between DPSCs and the immune system may be 
important to individualize the full potential of these cells. DPSCs immune-profile is 
regarded as non-immunogenic and accordingly transplantation into an allogenic host 
may not require immunosuppression. Otherwise, traditional heterologous 
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transplantation requires lifelong immunosuppression to avoid rejection. The application 
of DPSCs in tissue engineering may be a new strategy to limitate immunosuppressive 
therapy in stem cell heterologous transplantation. 
Future prospects  
 The dosage reduction of the immunosuppressive treatments necessary to prevent 
rejection against the DPSC/scaffold construct, due to DPSCs 
immunosuppressive effects.  
If necessary, the immunosuppressive therapy may be limited to the period               
required for a resumption of normal osteogenic activity in the host cells. 
Autologous or heterologous DPSC transplantation may promote transplant 
tolerance, even without immunosuppressive treatment.  
 The interactions between DPSC/scaffold and the new bone products after 
surgical intervention. The application of stem-colonized implant promotes tissue 
regeneration, also involving host cells: it may be possible that DPSCs lose their 
functions when specialized cells from the host start to repair the bone mass 
defect. 
In conclusion, these aspects suggest that DPSC/scaffold construct may have an 
expanded clinical applicability in the future and may represent a viable therapeutic 
option for those who would benefit from tissue replacement or repair. 
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DISCUSSION: PLACENTA 
 
Human placenta, besides playing a fundamental and essential role in fetal development, 
nutrition and tolerance, may also represent a reserve of progenitor/stem cells. 
Considering the complexity of the structure of the placenta, we focused our attention on 
fetal membranes, which extend from the margins of the chorionic disc and enclose the 
fetus in the amniotic cavity with the amniotic fluid (Parolini O et al., 2008). The 
chorionic membrane (chorion leave) consists of mesodermal and throphoblastic region: 
chorionic and amniotic mesoderm are similar in composition. A large and incomplete 
basal lamina separates chorionic mesoderm from the extravillus trophoblast cells that 
are dispersed within the fibrinoid layer. The Langhans fibrinoid layer usually increase 
during pregnancy and is composed of two different types of fibrinoid substance: a 
matrix type on the inner side (more compact) and a fibrin type in the outer side (more 
reticulate).  
De Coppi (2007) recently reported that amniotic fluid stem (AFS) cells can be obtained 
routinely from human amniotic fluid, using backup cells from amniocentesis specimens 
that would otherwise be discarded. AFS cells are pluripotent stem cells capable of 
giving rise to multiple lineages including representatives of all three embryonic germ 
layers, with an hold potential for a variety of therapeutic applications. 
These results did not revealed where in the amniotic membrane they were located or 
whether similar cells might be present in other placental tissue (i.e. chorionic 
membrane). Miki (2007) restricted the presence of stem cell marker-positive cells to the 
amniotic epithelia  and concluded that they are not present in other parts of the placenta. 
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Our preliminary studies, to identify the microenvironment, or niche, of stem/progenitor 
cells in the chorionic membrane, suggested different conclusions. 
The stem cells niche is a highly balanced microenvironment that allows stem cells to 
survive and remain quiescent and then respond by replicating, migrating and 
differentiating to replace or repair tissue, when needed (Castrechini  NM et al., 2010). 
The identification of the anatomic location of a stem cell niche within the chorionic 
membrane, and then within the chorionic villi, not only provides clues as to the nature 
of internal/external stimuli that regulated intracellular signals, but can also reveal 
additional roles for stem cells in the placental development and function. 
Immunohistochemical and immunofluorescence analysis on term placental sections 
were used to identify the stem cells localization.  
-Characterization on placental sections 
For a first characterization, a cell surface marker staining was performed with a specific 
antibody against c-Kit, the receptor of stem cell factor (SCF). This surface marker- 
receptor protein is present on human ES cells, primordial germ cells and many somatic 
stem cells, including, but not limited to, those of the neural crest. 
Later in pregnancy, c-Kit is expressed in the cytotrophoblast cells, the intermediate 
trophoblast cells, Hofbauer cells, and decidual macrophages and is not expressed in the 
syncytiotrophoblast cells. In our samples, a considerable staining pattern was detected 
in fibroblast-like cells around the blood vessels. These fibroblast-like cells, as described 
by Castrechini ( 2010) are consistent with the proposed model of mesenchymal stem 
cells lying in, or attached to, the basement membrane opposed to the endothelial cells. 
Mesenchymal stem cells showed a perivascular cell phenotype both in vitro and in vivo. 
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A population of placenta c-Kit
+
 cells detected in the chorionic villi is composed by 
pericyte-like cells: in vivo studies provided evidence that perycite may act as a source of 
undifferentiated cells during adipose or osseous tissue repair (Diaz-Flores L et al., 
1992). 
There may be multiple sub-populations of mesenchymal stem cell in the chorionic side 
of term placenta. In fact, the staining distribution showed another specific spatial 
location of c-Kit positive cells: a cell subpopulation,  with a strong cytoplasmatic c-Kit
+
 
staining, was localized in the peri-chorionic connective tissue and was characterized by 
big cells surrounded by Langhans fibrinoid deposit, close to the connective tissue.  
A further aim of the present study was to investigate whether cells with phenotypic and 
functional characteristics of pluripotent stem cells were present within human placenta 
(chorionic side). We detected the presence of Oct4, a transcription factor that plays a 
crucial role in maintaining pluripotency of embryonic stem cells. Down-regulation of 
Oct4 is associated with the differentiation of trophectoderm cell lineage, from which the 
normal placenta derives. Oct4-positive cells were localized in the same region of a 
subpopulation of c-Kit
+
 cells: positive-nuclei were detected in single-round cells, with 
an extended cytoplasm, similar to c-Kit
+
 cells located in the connective tissue, in the 
peri-chorionic side.  
Another Oct4
+
 population, distinct from the Oct4
+
 and c-Kit
+
 population previously 
described, were additionally found close to the sincytiotrophoblast layer. Isolated Oct4
+
 
cells  were present both in the connective-mesenchymal layer (Fig. 23D), as near the 
edge of the villus, close to the syncitiotrophoblast cells (Fig. 23C-E). 
Immunohistochemical analysis showed a strong nucleoplasmatic staining, in cells with a 
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simple cytoplasmatic organization, as a sign of multipotentiality, typical of cells 
metabolically quiescent.   
Little is known about the functional role of these pluripotency markers in adult stem 
cells. It has been shown that knockdown of Oct4 in human bone marrow MSCs induces 
changes in cell morphology, decrease growth rates and shifts cells from a cycling to a 
non-cycling state. Therefore, similar regulatory mechanism has been suggested for Oct4 
in both ESCs and MSCs (Riekstina U et al., 2009). As well as for the AFS, the surface 
marker profile and the expression of the transcription factor Oct4 suggest that they may 
represent an intermediate stage between pluripotent ES cells and lineage-restricted adult 
stem cells. 
To identify the stem potentiality of these cells, various combinations of intracellular 
markers or cells surface markers were studied in order to characterize the placental cells 
phenotype (Castrechini NM et al., 2010). 
Stella, a pluripotent marker expressed in primordial germ cells, in oocytes and in cells 
of the inner mass of blastocyst, shows nuclear staining in cells close to the 
syncytiotrophoblast layer, that, as reported by Ahamed et al. (2005), during normal 
gestation, derived by  the fusion of the cytrotrophoblastic cells.  The nuclear staining of 
these cells is of high intensity, as well as Oct4 positive staining. Positive cells were 
solitary and scattered on the mesenchyma, close to the syncytiotrophoblast:  surrounded 
by fibrinoid deposits, Stella positive cells are identically distributed as Oct4 positive 
cells, but they did not express c-Kit. 
 In summary we localized cells at different stages of differentiation in distinct part of the 
tissue analyzed: c-Kit positive cells in the peri-vascular tissue, big-round cells in the 
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connective tissue positive both for c-Kit as for Oct4 and cells that expressed positive 
staining for Oct4 and Stella, close to the syncytiotrophoblast. Cytotrophoblasts, a self-
renewing population located in the proliferation zone, form the multinucleate 
syncytiotrophoblasts (Spitalieri P et al., 2009): syncytiotrophoblast cells are terminally 
differentiated, but our results showed Oct4 and Stella nuclear positive staining in the 
same region. 
-Characterization of placental-cells in vitro 
The distribution of stem cells marker-positive cells in the chorionic tissue, is important 
to better understand their function and theirs potentiality; at the same time, it is 
necessary to isolate and then characterized chorion-derived stem cells from the term 
placenta at delivery, for further clinical applications. Our immunohistochemical/ 
immunofluorescence results, as previously described, suggests that isolated cells from 
chorionic membrane may be stem cells.  
Cells were isolated from placental tissue after a mechanical peeling of amnion 
membrane from the underlying chorion; a small sample of chorion (a cube of 2cm) was 
digested in a enzymatic solution, centrifugated and the released cells were cultured (all 
protocols are described in  M&M) on untreated plastic cultureware. 
Using a similar protocol as described by De Coppi (2007), we sorted c-Kit
+
 cells, with 
MACS® technology. C-Kit positive cells represented about 90 % of the selected cells, 
as confirmed by the FACS analysis: this percentage showed an homogeneous 
population with stem characteristics. In fact, CD117 (c-Kit), the surface marker used for 
immunoselection of AFS cells, plays an important role in gametogenesis, 
melanogenesis and hematopoiesis. This receptor protein is present on human ES cells, 
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primordial germ cells and many somatic stem cells, including, but not limited to, those 
of the neural crest. Cultured human c-Kit
+
 placental-cells were still positive for c-Kit
+
 
also after 20 days of culture, in -MEM medium supplemented with 20% FCS. The 
immunophenotype of chorionic-derived stem cells was similar to that of adult bone 
marrow mesenchymal stem cells, as described by Habdulrazzak et al (2010). Double 
immunofluorescence labeling was carried out to confirm the membrane-localization of 
c-Kit in cultured cells.  
When cultured in vitro, c-Kit
+
 cells maintain undifferentiated characteristics and 
pluripotency:   this was confirmed by the presence of a subpopulation of c-Kit
+
 cells 
that expressed transcript for Oct4 (as reported in PCR results), which is crucial for 
maintaining stemness, both in mouse and human embryonic stem cells (Spitalieri P et 
al., 2009).  
WB analysis showed that Oct4 was expressed both in c-Kit
+
 and in “not selected” 
protein extracts. In c-Kit
-
 lysates Oct4 expression was not detectable. These data 
confirmed the immunohistochemical results: in the connective tissue  some cells were c-
Kit
+
 and Oct4
+
 (see Fig. 22-23 Results). The whole lysates of “not selected” 
populations, showed a slightly positivity for Oct4, due to the co-presence of the two 
populations, c-Kit
+
 and c-Kit
-
. 
The staining distribution and the expression of c-Kit
+
 and Oct4
+
 in isolated placenta 
cells suggests a spatial location or a stem cell niche within the chorionic villi. This 
subpopulation may act as a source of undifferentiated cells, with a gradient of stemness 
inside the chorionic tissue: pericyte-like cells  are c-Kit
+
, mesenchymal stem cells in the 
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connective tissue are c-Kit
+
 and Oct4
+
, while cells close to the edge of the chorionic 
villi, are Stella
+
, like germ cells.   
-Conclusions 
Among the many cell types that may prove useful to regenerative medicine, mounting 
evidence suggests that human term placenta-derived cells will join strategies in clinical 
reality. Cells can be isolated during ongoing pregnancy using minimally invasive 
techniques such as chorionic villus sampling (CVS), or isolated from placental tissues 
readily available at delivery (Abdulrazzak  H  et al., 2010). The availability of placenta-
derived progenitor/stem cells are useful characteristics for cell therapy and tissue 
engineering. 
The development of cell therapy approaches using these cells may also benefit from the 
fact that placental tissues harbor different cell types that may complement each other in 
a clinical setting. Furthermore, aside from being easily procured in a painless and 
noninvasive manner, placental cells also offer additional advantages over stem cells 
from other sources such as bone marrow, which carry a risk of viral infection and show 
decreasing differentiation capacity with increasing donor age. Finally, it is tempting to 
speculate that placenta-derived cells may also be preferable from an immunological 
point of view, given the unique role of this tissue in maintaining fetomaternal tolerance 
throughout pregnancy and supported by the finding that placental cells show a greater 
capacity to down-regulate T-cell proliferation in vitro compared to bone marrow-
derived cells (Parolini O et al., 2008).   
 
 
 127 
REFERENCES 
 
1. Abdulrazzak H, Moschidou, D, et al. Biological characteristics of stem cells from 
foetal, cord blood and extraembryonic tissues. J R Soc Interface. 689-706,2010. 
2. Adewumi O, et al. Characterization of human embryonic stem cell lines by the 
International Stem Cell Initiative. Nat Biotechnol.  25(7): 803-16, 2007. 
3. Alison MR, Islam S. Attributes of adult stem cells. J Pathol. 217: 144–160, 2009. 
4. Altman GH, Diaz F, et al. Silk-based biomaterials. Biomaterials. 24(3): 401–16, 
2003.  
5. Anderson DJ, Gage, FH, et al. Can stem cells cross lineage boundaries? Nat 
Med. 7: 393–395, 2001. 
6. Arai F, Hirao A, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic 
stem cell quiescence in the bone marrow niche. Cell. 118: 149–161, 2004. 
7. Aronow MA, Gerstenfeld LC, et al. Factors that promote progressive 
development of the osteoblast phenotype in cultured fetal rat calvaria cells. J Cell 
Physiol. 143: 213-221, 1990. 
8. Assady S, Maor G, et al. Insulin production by human embryonic stem cells. 
Diabetes. 50: 1691– 1697, 2001. 
9. Atala A. Tissue engineering in the genitourinary system. In Tissue Engineering. 
Edited by Atala A, Mooney DJ. Birkhauser Press 149, 1997. 
10. Atala A. Engineering Organs. Current Opinion in Biotechnology. 20: 575–592, 
2009. 
 128 
11. Atala A, Freeman MR, et al. Implantation in vivo and retrieval of artificial 
structures consisting of rabbit and human urothelium and human bladder muscle. 
J Urol.  150: 608-612, 1993. 
12. Bailo M, et al.  Engraftment potential of human amnion and chorion cells derived 
from term placenta. Transplantation. 78: 1439–1448, 2004. 
13. Banerjee C, Javed A, et al. Differential regulation of the two principal 
Runx2/Cbfa1 N-terminal isoforms in response to bone morphogenetic protein-2 
during development of the osteoblast phenotype. Endocrinology. 142: 4026-
4039, 2001. 
14. Battula VL, et al.  Human placenta and bone marrow derived MSC cultured in 
serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-
4 and give rise to multilineage differentiation. Differentiation. 75: 279–291, 
2007. 
15. Bellows CG, Aubin JE, et al. Physiological concentrations of glucocorticoids 
stimulate formation of bone nodules from isolated rat calvaria cells in vitro. 
Endocrinology. 121: 1985–1992, 1987. 
16. Benirschke K, Kaufmann P. Pathology of the human placenta. New York; 
Springer-Verlag, 42– 46; 116: 281–297, 2000. 
17. Bianco P, Riminucci M, et al. Bone marrow stromal stem cells: nature, biology, 
and potential applications. Stem Cells. 19: 180–192, 2001. 
18. Bieback K, Kern S, et al. Critical parameters for the isolation of mesenchymal 
stem cells from umbilical cord blood. Stem Cells. 22: 625–634, 2004. 
 129 
19. Blau HM, Brazelton TR, et al. The evolving concept of a stem cell: Entity or 
function? Cell. 105: 829–841, 2001. 
20. Bondar B, Fuchs S, et al. Functionality of endothelial cells on silk fibroin nets: 
comparative study of micro- and nanometric fibre size. Biomaterials. 29(5): 561–
72, 2008. 
21. Boukhechba F, Balaguer T, et al. Human Primary Osteocyte Differentiation in a 
Three-Dimensional Culture System. J Bone Miner Res.  24(11): 1927-35, 2009. 
22. Brooke G, Rossetti T, et al. Manufacturing of human placenta-derived 
mesenchymal stem cells for clinical trials. Br J Haematol. 144: 571 – 579, 2009. 
23. Cananzi M, Atala A et al. Stem cells derived from amniotic fluid: new potentials 
in regenerative medicine. Reprod  Biomed  Online. 18(1): 17–27, 2009. 
24. Caplan AI. Mesenchymal stem cells. J Orthop Res. 9: 641–650, 1991. 
25. Caplan AI. Mesenchymal stem cells: cell-based reconstructive therapy in 
orthopedics. Tissue Eng. 11: 1198–211, 2005. 
26. Castrechini NM, Murthi, P, et al. Mesenchymal stem cell in human placental 
chorionic villi reside in a vascular Niche. Placenta. 31: 203-212, 2010. 
27.  Choumerianou DM, Dimitriou H, et al. Stem Cells: promises versus limitations 
tissue engineering. Part B Volume 14, 2008. 
28. Cilento BG, Freeman MR, et al. Phenotypic and cytogenetic characterization of 
human bladder urothelia expanded in vitro. J Urol. 152: 665-670, 1994. 
29. Civitelli R. Cell-cell communication in the osteoblast/osteocyte lineage. Arch 
Biochem Biophys. 473(2): 188-192, 2008. 
 130 
30. Csaki C, Matis U, et al. Co-culture of canine mesenchymal stem cells with 
primary bone-derived osteoblasts promotes osteogenic differentiation. Histochem 
Cell Biol. 131: 251–266, 2009. 
31. Cunningham FG, MacDonald PC, et al. The placenta and fetal membranes.  
Williams Obstetrics. 20th ed. Stamford, CT: Appleton and Lange, 95–125, 1997. 
32. Czyz J, Wiese C. Potential of Embryonic and Adult Stem Cells in vitro. Biol 
Chem. 384: 1391–1409, 2003. 
33. D’Aquino R, Papaccio G, et al. Dental Pulp Stem Cells: a promising tool for 
bone regeneration. Stem Cell Rev. 4: 21–26, 2008. 
34. Daley GQ, Scadden DT, et al. Prospects for stem cell-based therapy. Cell. 
132(4): 544–548, 2008. 
35. De Coppi  P, Bartsch G, et al.  Isolation of amniotic stem cell lines with potential 
for therapy. Nature Biotechnology. 25(1): 100–106, 2007. 
36. Deliloglu-Gurhana SI, Vatanseverb HS, et al. Characterization of osteoblasts 
derived from bone marrow stromal cells in a modified cell culture system . Acta 
Histochemica. 108: 49–57, 2006. 
37. Dezawa M, Ishikawa H, et al. Bone marrow stromal cells generate muscle cells 
and repair muscle degeneration. Science. 309(5732): 314–317, 2005. 
38. Donzelli E, Salvadè A, et al. Mesenchymal stem cells cultured on a collagen 
scaffold: In vitro osteogenic differentiation. Arch Oral Biol. 52(1): 64-73, 2007. 
39. Fang D, Nguyen TK, et al. A tumorigenic subpopulation with stem cell 
properties in melanomas. Cancer Res. 65: 9328 –9337, 2005. 
 131 
40. Fauza D. Amniotic fluid and placental stem cells. Best Pract Res Clin Obstet 
Gynaecol. 18: 877–891, 2004. 
41. Ferrera D, Biassoni C, et al. Three-dimensional cultures of normal human 
osteoblasts: proliferation and differentiation potential in vitro and upon ectopic 
implantation in nude mice. Bone. 5: 718-725, 2002. 
42. Franceschi RT. The role of ascorbic acid in mesenchymal differentiation. 
Nutrition Rev. 50: 65–70, 1992. 
43. Franceschi RT, Iyer BS, et al. Effects of ascorbic acid on collagen matrix 
formation and osteoblast differentiation in murine MC3T3-E1 cells. J Bone 
Miner Res. 9: 843–854, 1994. 
44. Friedenstein AJ, Deriglasova UF, et al. Precursors for fibroblasts in different 
populations of hematopoietic cells as detected by the in vitro colony assay 
method. Exp Hematol. 2: 83–92, 1974. 
45. Friedenstein AJ, Gorskaja JF, et al. Fibroblast precursors in normal and irradiated 
mouse hematopoietic organs. Exp Hematol. 4: 267–274, 1976. 
46. Friedenstein AJ, Pettakova KV, et al. Heterotopic transplants of bone marrow. 
Analysis of precursor cells for osteogenic and hematopoietic tissues. 
Transplantation. 6: 230-247, 1968. 
47. Fukuchi Y, Nakajima H, et al. Human placenta-derived cells have mesenchymal 
stem/progenitor cell potential. Stem Cells. 22: 649–658, 2004. 
48. Ganss B, Kim RH, et al. Bone sialoprotein. Crit Rev Oral Biol Med. 10(1): 79–
98, 1999. 
 132 
49. García-Pacheco JM, Oliver C, et al. Human decidual stromal cells express CD34 
and STRO-1 and are related to bone marrow stromal precursors. Mol Hum 
Reprod. 7(12): 1151-7, 2001. 
50. George J, Kuboki Y, et al. Differentiation of Mesenchymal Stem Cells Into 
Osteoblasts on Honeycomb Collagen Scaffolds. Biotechnology and 
Bioengineering. 95:  3, 2006. 
51. Gericke A, Qin,C, et al. Importance of phosphorylation for osteopontin 
regulation of biomineralization.  Calcif Tissue Int. 77(1): 45–54, 2005. 
52. Gigante A, Manzotti S, et al. Adult mesenchymal stem cells for bone and 
cartilage engineering: effect of scaffold materials. Eur J Histochem. 52(3): 169-
74, 2008. 
53. Graziano A, D'Aquino R, et al. Dental pulp stem cells: a promising tool for bone 
regeneration. Stem Cell Rev. 4(1): 21-26, 2008. 
54. Griffiths MJ, Bonnet D, et al. Stem cells of the alveolar epithelium. Lancet. 366: 
249–260, 2005. 
55. Gronthos S, Brahim J, et al. Stem cell properties of human dental pulp stem cells. 
J Dent Res. 81(8): 531-5, 2002. 
56. Gronthos S, Graves SE, et al. The STRO-1+ fraction of adult human bone 
marrow contains the osteogenic precursors. Blood. 84(12): 4164-4173, 1994. 
57. Gronthos S, Mankani M, et al. Postnatal human dental pulp stem cells (DPSCs) 
in vitro and in vivo. PNAS. 97: 13625, 2000. 
 133 
58. Gronthos S, Zannettino AC, et al. Molecular and cellular characterisation of 
highly purified stromal stem cells derived from human bone marrow. J Cell Sci. 
116: 1827–1835, 2003. 
59. Guillot PV, Gotherstrom C, et al. Human first trimester fetal mesenchymal stem 
cells (MSC) express pluripotency markers, grow faster, and have longer 
telomeres compared to adult MSC. Stem Cells. 25: 646–654, 2007. 
60. Haeckel E. (1877) Anthropogenie. Leipzig: Wilhelm Engelmann. 
61. Haseltine W. A brave new medicine. A conversation with William Haseltine 
Interview by Joe Flower. Health Forum J.  42: 28-30, 1999. 
62. Heng BC, Haider HK, et al. Strategies for directing the differentiation of stem 
cells into the cardiomyogenic lineage in vitro. Cardiovasc Res. 62: 34-42, 2004.  
63. Hipp J, Atala A. Sources of Stem Cells for Regenerative Medicine. Stem Cell 
Rev. 4: 3–11, 2008. 
64. Hochedlinger K, Jaenisch R, et al. Nuclear reprogramming and pluripotency. 
Nature. 29; 441(7097): 1061-7, 2006. 
65. Hochedlinger K, Yamada Y, et al. Ectopic expression of Oct-4 blocks 
progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 6; 
121(3): 465-77, 2005. 
66. Hoffman LM, Carpenter MK. Characterization and culture of human embryonic 
stem cells. Nat Biotechnol. 23: 699–708, 2005. 
67. Huang GT-J, Gronthos S, et al. Mesenchymal Stem Cells Derived from Dental 
Tissues vs. Those from Other Sources: Their Biology and Role in Regenerative 
Medicine. J Dent Res. 88(9): 792–806, 2009. 
 134 
68. Hunter GK, Goldberg HA. Proc Natl Acad Sci USA. 90: 8562–8565, 1993. 
69. Hunter GK, Hauschka PV, et al. Nucleation and inhibition of hydroxyapatite 
formation by mineralized tissue proteins. Biochem J. 317(1): 59-64, 1996. 
70. Hwang WS, Roh, SI, et al.Science. 308: 1777–1783, 2005. 
71. Ishida Y, Tertinegg I, et al. Progesterone and dexamethasone stimulate 
proliferation and differentiation of osteoprogenitors and progenitors for 
adipocytes and macrophages in cell populations derived from adult rate 
vertebrae. J Bone Miner Res. 11: 921–930, 1996. 
72. Itskovitz-Eldor J, Schuldiner M,  et al. Differentiation of human embryonic stem 
cells into embryoid bodies comprising the three embryonic germ layers. Mol 
Med. 6: 88−95, 2000. 
73. Jäger M, Feser T, et al. Proliferation and osteogenic differentiation of 
mesenchymal stem cells cultured onto three different polymers in vitro. Ann 
Biomed Eng. 33(10): 1319-1332, 2005. 
74. Kakishita K, Nakao N, et al. Implantatation of human amniotic epithelial cells 
prevents the degeneration of nigral dopamine neurons in rats with 6- 
hydroxydopamine lesions. Brain Res. 980: 48–56, 2003. 
75. Kärner E, Bäckesjö,CM. et al.  Dynamics of gene expression during bone matrix 
formation in osteogenic cultures derived from human embryonic stem cells in 
vitro. Biochim Biophys Acta. 1790(2): 110-118, 2008. 
76. Karsenty G, Wagner EF. Dev Cell 2(4): 389–406, 2002. 
77. Kaufman DS, Thomson JA. Human ES cells –haematopoiesis and transplantation 
strategies. J Anat. 200: 243–248, 2002. 
 135 
78. Kleinman HK, Martin GR. Matrigel: Basement membrane matrix with  
biological activity. Semin Cancer Biol. 15: 378–386, 2005. 
79. Koga T,  Matsui M, et al. NFAT and Osterix cooperatively regulate bone 
formation. Nat Med. 11(8): 880–885, 2005.  
80. Koike M, Sakaki S, et al. Characterization of embryoid bodies of mouse 
embryonic stem cells formed under various culture conditions and estimation of 
differentiation status of such bodies. J Biosci Bioeng. 104: 294−299, 2007. 
81. Kolf C, Cho E, et al. Mesenchymal stromal cells. Biology of adult mesenchymal 
stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res 
Ther. 9: 204, 2007. 
82. Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell 
Biochem. 99(5): 1233−1239, 2006. 
83. Kubo M, Sonoda Y, et al. Immunogenicity of human amniotic membrane in 
experimental xenotransplantation. Invest Ophthalmol Vis Sci. 42: 1539–1546, 
2001. 
84. Kuhn NZ, Tuan RS. Regulation in stemness and Stem cell niche of mesenchymal 
stem cells: implication in tumorigenesis and metastasis. J Cell Physiol. 222: 268-
277, 2009. 
85. Kuo MY, Lan WH, et al. Collagen gene expression in human dental pulp cell 
cultures. Arch Oral Biol. 37: 945-952, 1992. 
86. Laino G, D'Aquino R, et al. A new population of human adult dental pulp stem 
cells: a useful source of living autologous fibrous bone tissue (LAB). J Bone 
Miner Res. 20(8): 1394-1402, 2005. 
 136 
87. Laino G, Graziano A, et al. An approachable human adult stem cell source for 
hard-tissue engineering. J Cell Physiol. 206: 693–701, 2006. 
88. Langer R, Vacanti JP. Tissue engineering. Science. 260(5110): 920–6, 1993. 
89.  Laschke MW, Rucker M. Incorporation of growth factor containing Matrigel 
promotes vascularization of porous PLGA scaffolds. J Biomed Mater Res. 85A: 
397–407, 2008. 
90. Lavker RM, Tseng SC, et al. Corneal epithelial stem cells at the limbus: Looking 
at some old problems from a new angle. Exp Eye Res. 78: 433– 446, 2004. 
91. Lee SY, Miwa M, et al. In vitro multipotentiality and characterization of human 
unfractured traumatic hemarthrosis-derived progenitor cells: a potential cell 
source for tissue repair. J Cell Physiol. 210: 561–566, 2007. 
92. Li L, Xie T. Stem cell niche: Structure and function. Annu Rev Cell Dev Biol. 
21: 605– 631, 2005. 
93. Lian JB, Shalhoub V, et al. Species-specific glucocorticoid and 1,25-
dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: 
Dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates 
osteocalcin gene expression. Endocrinology. 138: 2117–2127, 1997. 
94. Liebert M, Hubbel A, et al. Expression of mal is associated with urothelial 
differentiation in vitro: identification by differential display reverse-transcriptase 
polymerase chain reaction. Differentiation. 61: 177-185, 1997. 
95. Liu L, Sun Z, et al. Ex vivo expansion and in vivo infusion of bone marrow-
derived Flk-1+CD31–CD34– mesenchymal stem cells: feasibility and safety 
from monkey to human. Stem Cells Dev. 15: 349–357, 2006. 
 137 
96. Liu W, Toyosawa S, et al. J Cell Biol. 155(1): 157–166, 2001. 
97. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 25: 402-
408, 2001. 
98. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular 
microenvironments for morphogenesis in tissue engineering. Nature 
Biotechnology. 23(1): 47–55, 2005. 
99. Magatti M, De Munari S, et al. Human amnion mesenchyme harbors cells with 
allogeneic T cell suppression and stimulation capabilities. Stem Cells. 182-192, 
2007. 
100. Maltepe E, Bakardjiev AI, et al. The placenta: transcriptional, epigenetic, and 
physiological integration during development. J Clin Invest. 120(4): 1016–1025, 
2010. 
101. Marco F, Lopez-Oliva F, et al. Osteochondral allografts for osteochondritis 
dissecans and osteonecrosis of the femoral condyles. Int Orthop. 17: 104–108, 
1993. 
102. Marcus A, Woodbury D. Fetal stem cells from extraembryonic tissues: do not 
discard. J Cell Mol Med. 12: 730–742, 2008. 
103. Marie PJ. Transcription factors controlling osteoblastogenesis. Arch Biochem 
Biophys. 473(2): 98-105, 2008. 
104. Martin GR. Isolation of a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad 
Sci USA, 78: 7634-7638, 1981. 
 138 
105. McCulloch CAG, Fair C, et al. The regulatory effect of phosphates on bone 
metabolism in vitro. Cell Tissue Res. 257: 555-563, 1989. 
106. McKee MD, Nanci A. Osteopontin and the bone remodeling sequence. 
Colloidal-gold immunocytochemistry of an interfacial extracellular matrix 
protein. Ann. NY Acad Sci. 760: 177–189, 1995a. 
107. Mimeault M, Batra SK. Concise Review: Recent Advances on the Significance 
of Stem Cells in Tissue Regeneration and Cancer Therapies. Stem Cells. 24: 
2319–2345, 2006. 
108. Mitsui K, Tokuzawa Y,  et al. The homeoprotein Nanog is required for 
maintenance of pluripotency in mouse epiblast and ES cells. Cell. 30; 113(5): 
631-42, 2003. 
109. Miura M, Gronthos S, et al. SHED: stem cells from human exfoliated deciduous 
teeth. Proc Natl Acad Sci USA.  100: 5807, 2003. 
110. Mizuno H, Zuk PA, et al. Myogenic differentiation by human processed 
lipoaspirate cells. Plast Reconstr Surg. 109: 199–209, 2002. 
111. Modlin IM, Kidd M, et al. Gastric stem cells: An update. Keio J Med. 52: 134 –
137, 2003. 
112. Morsczeck C, Gotz W, et al. Isolation of precursor cells (PCs) from human 
dental follicle of wisdom teeth. Matrix Biol. 24: 155–165, 2005. 
113. Nagata T, Bellows CG, et al. Biosynthesis of bone proteins ISPP-1 (secreted 
phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC 
(osteonectin) in association with mineralized-tissue formation by fetal-rat 
calvarial cells in culture. Biochem J. 274: 513–20, 1991. 
 139 
114. Nakamura T, Arai Y, et al. PGC7/Stella protects against DNA demethylation in 
early embryogenesis. Nat Cell Biol. 9: 64–71, 2007. 
115. Nakashima K, Zhou J, et al. MANCA TITOLO Cell. 108(1): 17–29, 2002. 
116. Nelson TJ, Behfar A. Stem Cell Platforms for Regenerative Medicine. Clin 
Transl Sci. 1; 2(3): 222–227, 2009. 
117. Niwa H, Miyazaki J, et al.Quantitative expression of Oct-3/4 defines 
differentiation, dedifferentiation or self-renewal of ES cells. Nat Gene. 24(4): 
372-6, 2000. 
118. O’Donoghue K, Fisk NM. Fetal stem cells. Best Pract Res Clin Obstet 
Gynaecol. 18: 853–875, 2004.  
119. Oyama S. The Ontogeny of Information. Developmental Systems and Evolution. 
Raleigh, NC: Duke University Press. 2000.  
120. Palumbo C, Ferretti M, et al. Osteocyte dendrogenesis in static and dynamic 
bone formation: an ultrastructural study. Anat Rec A Discov Mol Cell Evol Biol, 
278(1): 474-480, 2004. 
121. Pandipati S, Driscoll JE, et al. Glucocorticoid Stimulation Of Na/- Dependent 
Ascorbic Acid Transport In Osteoblast-Like Cells. J Cell Physiol. 176: 85–91, 
1998. 
122. Papaccio G, Graziano A, et al.  Long-term cryopreservation of dental pulp stem 
cells (SBP-DPSCs) and their differentiated osteoblasts: a cell source for tissue 
repair. J Cell Physiol. 208: 319–325, 2006. 
 140 
123. Parolini O, Alviano F, et al. Toward Cell Therapy Using Placenta-Derived Cells: 
Disease Mechanisms, Cell Biology, Preclinical Studies, and Regulatory Aspects 
at the Round Table Stem Cells And Development. Volume 19, Number 2, 2010. 
124. Parolini O, Alviano F, et al. Concise Review: Isolation and Characterization of 
Cells from Human Term Placenta: Outcome of the First International Workshop 
on Placenta Derived Stem Cells. Stem Cells. 26: 300 –311, 2008. 
125. Patrick JG, Barry JJA, et al. Controlling protein release from scaffolds using 
polymer blends and composites. European Journal of Pharmaceutics and 
Biopharmaceutics. 68: 82–89, 2008. 
126. Payer B, Saitou M, et al. Stella is a maternal effect gene required for normal 
early development in mice. Curr Biol. 13: 2110–2117, 2003.  
127. Phinney DG. Building a consensus regarding the nature and origin of 
mesenchymal stem cells J Cell Biochem. 38: 7–12, 2002. 
128. Pierdomenico L, Bonsi L, et al. Multipotent Mesenchymal Stem Cells with 
Immunosuppressive Activity Can Be Easily Isolated from Dental Pulp. 
Transplantation. 80: 836–842, 2005. 
129. Pittenger MF, Mackay AM, et al. Multilineage potential of adult human 
mesenchymal stem cells. Science. 284: 143–147, 1999. 
130. Potten CS, Loeffler M. Stem cells: Attributes, cycles, spirals, pitfalls and 
uncertainties. Lessons for and from the crypt. Development. 110: 1001–1020, 
1990. 
131. Pratap J, Galindo M, et al. Cell growth regulatory role of Runx2 during 
proliferative expansion of preosteoblasts. Cancer Res. 63(17): 5357-5362, 2003. 
 141 
132. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. 
Science. 276: 71–74, 1997. 
133. Ramalho-Santos M, Willenbring H. On the origin of the term ‘‘stem cell’’. Stem 
Cell. 1: 335–338, 2007. 
134. Reubinoff BE, Itsykson P, et al. Neural progenitors from human embryonic stem 
cells. Nature Biotechnol. 19: 1134–1140, 2001. 
135. Reubinoff BE, Pera MF, et al. Embryonic stem cell lines from human 
blastocysts: somatic differentiation in vitro. Nature Biotechnol. 18: 399–404, 
2000. 
136. Riccio M, Resca E, et al. Osteogenic differentiation of human dental pulp stem 
cells in 3D scaffolds. EJH. 115,volume 45, number 4, 2010. 
137. Riekstina U, Cakstina I, et al.  Embryonic Stem Cell Marker Expression Pattern 
in Human Mesenchymal Stem Cells Derived from Bone Marrow, Adipose 
Tissue, Heart and Dermis. Stem Cell Rev and Rep. 5: 378–386, 2009. 
138. Seong JM, Kim BC. Stem cells in bone tissue engineering. Biomed. Mater. 
5:062010, 2010. 
139. Shamblott MJ, Axelman J, et al. Derivation of pluripotent stem cells from 
cultured human primordial germ cells. Proc Natl Acad Sci USA. 95: 13726– 
13731, 1998. 
140. Sila-Asna M, Bunyaratvej A, et al. Osteoblast differentiation and bone formation 
gene expression in strontium-inducing bone marrow mesenchymal stem cell. J 
Med Sci. 53(1-2): 25-35, 2007. 
 142 
141. Simmons PJ,  Torok-Storb B. CD34 expression by stromal precursors in normal 
human adult bone marrow. Blood. 78(11): 2848-2853, 1991. 
142. Sinanan AC, Hunt NP, et al. Human adult craniofacial muscle-derived cells: 
neural-cell adhesionmolecule (NCAM; CD56)-expressing cells appear to contain 
multipotential stem cells. Biotechnology and Applied Biochemistry. 40: 25–34, 
2004. 
143. Soncini M, Vertua E, et al. Isolation and characterization of mesenchymal cells 
from human fetal membranes. J Tissue Eng Regen Med. 1: 296 –305, 2007. 
144. Sonoyama W, Liu Y, et al. Mesenchymal stem cell-mediated functional tooth 
regeneration in Swine. PLoS. 1:79, 2006. 
145. Sonoyama W, Liu Y, et al. Characterization of the apical papilla and its residing 
stem cells from human immature permanent teeth: a pilot study. J Endod. 34: 
166–171, 2008. 
146. Spitalieri P, Cortese G, et al. Identification of Multipotent Cytotrophoblast Cells 
from Human First Trimester Chorionic Villi. Cloning and Stem Cells. 11(4): 
535-556, 2009. 
147. Stewart K, Walsh S, et al. Further characterization of cells expressing STRO-1 
in cultures of adult human bone marrow stromal cells. J Bone Miner Res. 14: 
1345–1356, 1999. 
148. Stojkovic M, Lako M, et al. Derivation, growth and applications of human 
embryonic stem cells. Reproduction. 128: 259–267, 2004. 
 143 
149. Sudo K, Kanno M, et al. Mesenchymal progenitors able to differentiate into 
osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most 
primary fibroblast-like cell populations. Stem Cells. 25: 1610–1617, 2007. 
150. Sun H, Feng K, et al. Osteogenic differentiation of human amniotic fluid-
derived stem cells induced by bone morphogenetic protein-7 and enhanced by 
nanofibrous scaffolds. Biomaterials. 31: 1133–1139, 2010. 
151. Thomas ML. The Leukocyte Common Antigen Family Annual Review of 
Immunology. 7: 339-369, 1989.  
152. Thomson JA, Itskovitz-Eldor J, et al. Embryonic stem cell lines derived from 
human blastocysts. Science. 282, 1145–1147, 1998. 
153. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of 
normal mouse bone marrow cells. Radiat Res. 14: 213–222, 1961. 
154. Tsai M, Lee J, et al. Isolation of human multipotent mesenchymal stem cells 
from second-trimester amniotic fluid using a novel two-stage culture protocol. 
Hum Reprod. 19: 1450–1456, 2004. 
155. Valenti MT, Dalle Carbonare L, et al. Gene expression analysis in osteoblastic 
differentiation from peripheral blood mesenchymal stem cells. Bone. 43(6): 
1084-1092, 2008. 
156. Walsh S, Jordan GR, et al. High concentrations of dexamethasone suppress the 
proliferation but not the differentiation or further maturation of human osteoblast 
precursors in vitro: relevance to glucocorticoid-induced osteoporosis. 
Rheumatology. 40(1): 74–83. 2001. 
157. Wang X, Kua HY, et al. J Cell Biol. 172 (1): 115–125, 2006. 
 144 
158. Wanga Y, Kimj  HJ, et al. Stem cell-based tissue engineering with silk 
biomaterials. Biomaterials. 27: 6064–6082, 2006. 
159. Weiss ML, Troyer  DL. Stem cells in the umbilical cord. Stem Cell Rev. 2: 155–
162, 2006. 
160. Wenisch S, Trinkaus K, et al. Immunochemical, ultrastructural and 
electrophysiological investigations of bone-derived stem cells in the course of 
neuronal differentiation. Bone. 38(6): 911-21, 2006. 
161. Wilson JX, Dixon SJ. High-affinity sodium-dependent uptake of ascorbic acid 
by rat osteoblasts. J Membrane Biol. 111: 83–91, 1989. 
162. Yoshimura K, Shigeura, T, et al. Characterization of freshly isolated and 
cultured cells derived from the fatty and fluid portions of liposuction spirates. J 
Cell Physiol. 208: 64–76, 2006. 
163. Yu J, He H, et al. Differentiation potential of STRO-1+ dental pulp stem cells 
changes during cell passaging. BMC Cell Biol. 8:11-32, 2010. 
164. Zavan B, Giorgi C, et al. Osteogenic and chondrogenic differentiation: 
comparison of human and rat bone marrow mesenchymal stem cells cultured into 
polymeric scaffolds. Eur J Histochem. 51(1): 1-8, 2007. 
165. Zhang W, Walboomers XF, et al.  Multilineage differentiation potential of stem 
cells derived from human dental pulp after cryopreservation. Tissue Eng. 12(10): 
2813-2823, 2006. 
166. Zhao HX, Li Y, et al. Rapid and efficient reprogramming of human amnion-
derived cells into pluripotency by three factors OCT4/SOX2/NANOG. 
Differentiation. 80(2-3): 123-9, 2010. 
 145 
167. Zhou J, Zhang  Y,  et al.  Embryoid bodies formation and differentiation from 
mouse embryonic stem cells in collagen/Matrigel scaffolds. J Genet Genomics. 
37:  451−460, 2010. 
